Sonic hedgehog signaling pathway in normal and adenomatous pituitary by Vila, Greisa
From:   Max Planck Institute of Psychiatry
Director: Professor Dr. Dr. F. Holsboer
Sonic hedgehog signaling pathway in normal
and adenomatous pituitary
Thesis for the attainment of the title Medical Doctor
from the Faculty of Medicine, Ludwig-Maximilians-University, Munich
Submitted  by  Greisa Vila 
Tirana
2004
2
Mit Genehmigung der Medizinischen Fakultät
der Universität München
Berichterstatter: Prof. Dr. G. K. Stalla
Mitberichterstatter: Prof. Dr. A. König
Prof. Dr. J. Herms
Mitbetreuung durch den 
Promovierten Mitarbeiter: Dr. rer. nat. M. Paez-Pereda
Dekan: Prof. Dr. med. Dr. h. c. K. Peter
Tag der mündlichen Prüfung: 18.03.2004
3
To Fiona
4
Table of Contents
         page
Abbreviations   6
1. Introduction   8
1.1  The pituitary gland and pituitary tumors   8
1.1.1 The pituitary gland   8
1.1.2 Regulation of corticotroph cells by CRH 11
1.1.3 Pituitary tumors 11
     1.2  Sonic hedgehog signal transduction pathway – an overview 12
     1.3  Sonic hedgehog signaling pathway in human disease 16
     1.4  Shh signaling in pituitary gland development 18
2.  Aim of the work 20
3.  Methods 21
3.1    Equipment 21
3.2    Reagents 22
3.3    Solutions  24
3.4    Human tissues 25
3.5    Immunohistochemistry 25
3.5.1 Single immunohistochemistry 28
3.5.2 Double immunohistochemistry 29
3.6 Cell culture 30
3.6.1 Rat pituitary primary cell culture 30
3.6.2 Immortalized pituitary cell lines 31
3.6.3 Stimulations 31
3.7 Hormone measurement by RIA 33
3.8 Cell proliferation measurement by WST-1 34
3.9 Western Blot 34
3.10  Transfections 36
3.10.1    Plasmids 36
3.10.2    Transformation 38
3.10.3    Transfection 39
3.11  Statistics 40
5
4.    Results 42
4.1   Members of the Sonic hedgehog pathway are expressed in the 42
    pituitary gland (Single and Double Immunohistochemistry results)
4.2   Sonic hedgehog increases ACTH and GH secretion in the normal rat   48
    pituitary
4.3     Sonic hedgehog effects on ACTH secretion in the AtT-20 cell line 52
      4.3.1   Shh increases ACTH secretion in AtT-20 cells 52
4.3.2 Shh and CRH / Forskolin have synergistic effects on 54
           ACTH secretion
4.4     Sonic hedgehog effect on hormone secretion in the GH3 cell line 56
     4.4.1   Shh increases Growth Hormone secretion 56
         4.4.2   Shh effect on Prolactin secretion 57
     4.5    Shh and CRH cross-talk at the protein level 58
     4.6    Shh pathway upregulates POMC transcriptional activity 60
4.6.1  Shh increases Gli1-Luc transcription
          Gli1 is a target of itself in the AtT-20 cell line 60
4.6.2  Gli1 increases POMC promoter transcription 63
     4.7    Shh and CRH pathway cross-talk at the transcriptional level 64
4.7.1  Gli1 is up-regulated by cAMP and CRH 64
4.7.2  Gli1 increases AP-1 and Cre transcriptional activity 66
4.8 Sonic hedgehog pathway members are downregulated in pituitary 67
   tumors 
4.9 Sonic hedgehog effect on cell proliferation in the AtT-20 and GH3 72
   cell lines
4.9.1  Shh reduces cell proliferation in the AtT-20 cell line 72
4.9.2  Shh has no impact on GH3 cell proliferation 74
5.    Discussion 75
6. Summary            83
6.1 Zusammenfassung 85
7. Bibliography 87
Acknowledgements 93
Curriculum Vitae 94
6
Abbreviations
ACRO Acromegaly
ACTH Adrenocorticotrophic hormone
AP Alkaline phosphatase
AP-1 Activator protein - 1
bp base pairs
BCC Basal cell carcinoma
cAMP cyclic adenosine monophosphate, cyclic AMP
Ci Cubitus interruptus
CK1 Casein kinase 1
CMV Cytomegalovirus
CNS central nervous system
Cos2 Costal 2
CRE cyclic AMP regulatory element
CREB cyclic AMP regulatory element binding protein
CRH Corticotropin releasing hormone
CRH-R1 CRH receptor 1
Cush Cushing tumor
DAB              Diaminobenzidine tetrahydrochloride
Disp Dispatched
Dhh Desert hedgehog
DMEM Dulbecco´s Modified Eagle´s Medium 
FCS Foetal calf serum
FSH Follicle-stimulating hormone
Fu Fused
GH Growth hormone 
GHRH Growth hormone releasing hormone
GFP Green fluorescent protein
GnRH Gonadotropin releasing hormone
GSK3 glycogen synthase kinase
Hh Hedgehog
Hip Hedgehog – interacting protein
IHC Immunohistochemistry
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Ihh Indian hegehog
LH Luteinizing hormone
NBCCS Nevoid basal cell carcinoma syndrome
NFPA Non-functioning pituitary adenoma 
PFA Paraformaldehyde
PKA Protein kinase A
PNET Primary neuro-ectodermal tumors
POMC Pro-opiomelanocortin
Prl Prolactin
Prol Prolactinoma
Ptc Patched 1 or Ptc1
RIA Radioimunoessay
Shh Sonic hedgehog
Shh -/- Shh deficient mouse
Shh-C Sonic hedgehog C-terminal polypeptide
Shh-N Sonic hedgehog N-terminal polypeptide
Smo Smoothened
Su(Fu) Suppressor of Fused
TRH Thyreotropin releasing hormone
TSH Thyrotropin or Thyroid-stimulating hormone
Tvt Tout-velu
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1.   INTRODUCTION
Signaling proteins function in a cellular environment to direct cells into a change of
state, such as promotion of proliferation or differentiation. 
Sonic hedgehog (Shh) is a signaling protein important in regulating patterning,
proliferation, survival and growth in both embryo and adult mammalian systems (1).
Sonic hedgehog is absolutely required for pituitary development: Shh -/- (Shh
deficient) mice do not have even a rudimentary Rathke’s pouch (the embryonic
structure that develops into the pituitary gland's anterior lobe). Shh is uniformly
expressed throughout the oral ectoderm, but its expression is restricted to the
Rathke’s pouch as soon as it becomes morphologically visible. This restriction exerts
effects on both pituitary cell proliferation and cell-type determination (2).
There are currently no studies on the expression and role of Shh pathway in the adult
pituitary gland. 
1. 1 The pituitary gland and pituitary tumors
1.1.1.  The pituitary gland
The pituitary gland has a vital role in maintaining physiological homeostasis under
basal and challenge conditions. It is roundish, weighs about 0,6 g and resides in the
sella turcica, a saddle-shaped depression in the sphenoid bone, where it has
important anatomic relations with the hypothalamus, cavernous sinus, carotid artery,
optic tracts and other cranial nerves. 
The pituitary gland in mammalian embryos originates through the interaction of the
neural and the oral ectoderm. The oral ectoderm grows upward from the roof of the
mouth and gives rise to the Rathke’s pouch, which then develops into the anterior
and intermediate pituitary gland, containing at least 6 distinct cell phenotypes (3, 4).
At the same time, another finger of ectodermal tissue evaginates ventrally from the
diencephalon of the developing brain. This extension of the ventral brain forms the
posterior pituitary or neurohypophysis. Ultimately, the two tissues grow tightly into
one another, but their structure remains distinctly different, reflecting their differing
embryological origins (presented schematically in Fig.1).
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 Fig. 1.  Pituitary gland embryology
The pituitary gland in mammalian embryos is formed through the interaction of the neural and
the oral ectoderm. The oral ectoderm grows upward from the roof of the mouth and forms the
Rathke’s pouch, the embryonic structure that gives rise to the pituitary gland's anterior lobe. At
the same time, the neural ectoderm evaginates ventrally creating an extension of the brain
which will give rise to the posterior pituitary gland.
The human pituitary gland is composed of two distinctive parts (Fig.2): 
- the anterior pituitary (adenohypophysis) is a classical gland composed
predominantly of cells that secrete protein hormones.
- the posterior pituitary (neurohypophysis) is an extension of the hypothalamus. It is 
composed largely of the axons of hypothalamic neurons which extend downward as
a large bundle behind the anterior pituitary. They also form the so-called pituitary
stalk, which appears to suspend the anterior gland from the hypothalamus.
The adenohypophysis is a complex gland containing different cell types. These cells
produce six principal hormones: three peptide hormones (GH, Prl and ACTH) and
three glycoprotein hormones (FSH, LH and TSH). 
Fig. 2. The pituitary gland
The pituitary gland is shown resting in the sella turcica,
a saddle-shaped depression in the sphenoid bone. The
antomical location under the optic chiasma and the
third ventricle is clearly seen.
The adenohypophysis contains different hormone
producing cells. The neurohypophysis contains axons
which mainly derive from the magnocellular neurons of
the hypothalamic supraoptic and paraventricular nuclei.
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Advances in ultrastructural techniques have made possible a functional classification
of these cells according to the hormones that they produce. This classification
includes: somatotrophs (GH-secreeting cells, acidophils), lactotrophs (prolactin-
secreting cells, mammotrophs, acidophils), mammosomatotrophs (few bihormonal
cells, producing both GH and prolactin, acidophils), corticotrophs (ACTH-secreting
cells, basophils), gonadotrophs (FSH/LH-secreting cells, basophils) and thyrotrophs
(TSH-secreting cells, basophils). 
The anterior pituitary also contains folliculostellate (FS) cells that appear in the
pituitary at the age of 5 months and have unique morphologic features (5). Their role
has become more evident recently.  The network of nonendocrine FS cells helps in
establishing an intrapituitary communication system: they respond to central and
peripheral stimuli and communicate with endocrine cells via growth factors and
cytokines, suggesting an important role in the paracrine regulation of hormone
secretion (6, 7). 
Hormone secretion by the anterior pituitary gland is under the positive-feedback
control of hypothalamic releasing factors (CRH, GHRH, GnRH, TRH), hypothalamic
inhibiting factors (dopamine, somatostatin) and under the negative-feedback control
of peripheral hormones (thyroxin, glucocorticoids, etc). 
The posterior lobe releases oxytocin and vasopressin from axon terminals that
originate in cell bodies located in the hypothalamus. 
The pituitary gland contains also an intermediate lobe, which is rudimentary in human
beings. Recently it has been established that it produces several hormones with
physiologic significance (reviewed in 8).
There is a large body of in vitro evidence that pituitary function is not only dependent
on hormonal signals from the brain but also on paracrine signals produced in the
tissue itself. These signals appear to be involved in the control of pituitary hormone
secretion as well as in pituitary cell differentiation and development. The paracrine
factors which have been identified in the pituitary belong to diverse biological
molecules such as neuropeptides, acetylcholine, growth factors, cytokines (9) and
posttranslationally modified derivatives of pituitary hormones.
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1.1.2  Regulation of corticotroph cells by CRH 
Hypothalamic corticotropin releasing hormone (CRH) stimulates pituitary ACTH
secretion through interaction with CRH receptors type 1 (CRH-R1) localized in
corticotrophs. CRH increases transcription of Pro-opiomelanocortin (POMC), the
ACTH precursor (10). This effect is mainly mediated by the cyclic-AMP (cAMP)
pathway. CRH stimulation of corticotroph cells results in an elevation of cAMP and
activation of protein-kinase A (PKA) which in turn plays important roles in activating
POMC expression. Other hormones and neuropeptides (e.g. glucocorticoids) also
modify POMC transcription by acting on the second messengers: cAMP and Ca++
(the calcium/calmodulin pathway) (11).
The POMC promoter does not have the classical cAMP responsive element,
although it was known that the effect of PKA activation on POMC was mediated
through the cAMP regulatory element binding protein (CREB). A novel POMC-cAMP-
responsive element (POMC-CRE) was identified in 1995 (12).
Activator protein-1 (AP-1) is another transcription factor induced by CRH. It binds
directly to POMC and is formed and regulated by the Jun and Fos family of proteins
(13, 14). However, deletion of the AP-1 binding site on POMC does not suppress
completely the CRH stimulation of POMC (15), indicating that other transcription
factors might also regulate POMC.
So, CRH stimulation of corticotroph cells involves different pathways and successive
recruitment of activators and repressors. Some of these pathways have been studied
but they do not fully explain the complex regulation of ACTH. Prompted by this and
by the crucial importance of Shh for pituitary development, we decided to study the
involvement of the Shh pathway in ACTH secretion and POMC transcription.
1.1.3  Pituitary tumors
Pituitary tumors are common neoplasms, reported to account for 10-15% of all
intracranial tumors, being so the second common neoplasms after meningeomas
(16). Their prevalence is 300 per 1000000 inhabitants. They are usually
nonmetastasizing neoplasms, which exhibit a wide range of clinical signs and
symptoms produced by hormone over secretion, hormone deficiency or mass effects.
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The pathogenesis of pituitary adenomas is very complex. Studies examining X-
chromosome inactivation in female patients  have shown that pituitary adenomas are
monoclonal. This is also supported by the lack of associated hyperplasia
accompanying pituitary adenomas. Nevertheless, tumor progression from a single
initiated cell requires stimulus for growth. In the pituitary gland, hypophysiotropic
hormones and growth and differentiation factors are the obvious candidates to be
implicated in the genesis and progression of these tumors. The above theory is
supported by several animal models and unusual clinical cases. The current
approach integrates these proposed theories: it is likely that the majority of pituitary
adenomas develop from transformed cells that are dependent on hormonal and/or
growth factor stimulation for tumor progression (reviewed in 17).
Recent studies of cell differentiation regulators in the adenohypophysis have led to a
more sophisticated understanding of the mechanisms that determine the patterns of
hormone production and cell proliferation in pituitary adenomas. There is evidence
that differentiating factors like retinoic acid (RA) and BMP4 which take part in co-
ordinating the control of progenitor cell identity, proliferation and differentiation in
anterior pituitary, play important roles in pituitary adenomas (18, 19). Sonic
hedgehog, one of the most important pathways involved in pituitary development and
differentiation, has not been studied in adult pituitary or in pituitary adenomas.
1.2  Shh signal transduction pathway – an overview 
Members of the hedgehog (hh) family encode a novel class of secreted proteins that
act as intercellular signals. Hedgehog was first identified by a genetic screen in the
fruit fly Drosophila melanogaster, described in the Nobel Prize winning work of C.
Nüsslein-Volhard and E. Wieshaus (20).
As with other developmental pathways first elucidated through genetic studies in
Drosophila melanogaster, the hedgehog pathway is also conserved in vertebrates.
Several hedgehog homologues have been isolated from various vertebrate species
(21, 22, 23). There are three mammalian hedgehog homologues: Sonic hedgehog
(Shh), Desert hedgehog (Dhh), and Indian hedgehog (Ihh).
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Shh has the largest known range of biological actions and is the only hedgehog
homologue present in the central nervous system (CNS). Shh is responsible for the
major effects on development of the brain, spinal cord, axial skeleton, limbs, pituitary
gland, lungs, gut, etc. Ihh has been implicated in the regulation of cartilage
differentiation and growth of long bones. Dhh exerts its effect mainly in the
developing germline and in Schwann cells of the peripheral nervous system
(reviewed in 24). With the exception of the gut, in which both Ihh and Shh are
expressed, the expression patterns of the hedgehog family members do not overlap. 
The primary Shh translation product includes a signal peptide, which is cleaved to
yield a 45-kDa precursor protein. Shh itself catalyses a second intramolecular
cleavage that generates a 20-kDa N-terminal polypeptide (Shh-N) containing all
known signaling functions of the molecule and a 25-kDa C-terminal polypeptide (Shh-
C), which appears to have no function other than catalyzing the autoproteolytic
cleavage (25, 26). 
The Shh-N is modified by the addition of a cholesterol moiety at its C-terminus (27).
The cholesterol modification is essential for the normal range of signaling (28) and it
is thought to be required for the correct spatial restriction of the actions of Shh. Due
to these modifications, Hedgehog proteins have been detected and act far from their
sources. Additional proteins are involved in Shh release and diffusion (reviewed in
29). These include Dispatched (Disp) and Tout-velu (Tvt). Dispatched is a 12-
transmembrane-domain protein with a sterol-sensing domain required for Hh release.
Ttv regulates synthesis of proteoglycans and functions to allow movement of Hh.
Details of Shh signaling pathway are given in Fig. 3.
Hedgehog signaling at the cell surface occurs via the Ptc-Smo receptor complex, a
multicomponent receptor complex involving Patched (Ptc, also known as Ptc1) and
Smoothened (Smo). Ptc is a 12-transmembrane-domain protein that binds to Shh
and Smo is a 7-transmembrane domain protein homologous to G-protein-coupled
receptors (reviewed in 30). In the absence of Shh, Ptc represses Smo. Shh binding to
Ptc releases the basal repression of Smo by Ptc and  activates the pathway, Smo
acts intracellularly to transduce the Hh signal to the nucleus.
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Figure 3.
Sonic hedgehog signaling pathway
Shh goes through an autocatalyzation that generates a C-terminal polypeptide and a N-terminal
polypeptide (the last containing all the signaling functions of the molecule). Shh binding to Ptc
releases the basal  repression of Smo by Ptc and activates the pathway. Smo transduces the
Shh signal to modify the Gli proteins. Gli1, the transcription factor (positive mediator) of the Shh
pathway, translocates to the nucleus where it promotes the expression of target genes e.g. Ptc1,
Ptc2, Gli1, etc.
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A second murine Patched gene, Ptc2 (also known as Ptch2), was discovered in 1998
(31). It is expressed in the adult eye and in epithelial cells of developing hair follicles,
teeth and whiskers. Both Ptc1 and Ptc2 are genuine hedgehog receptors capable of
recognizing the various hedgehog ligands (Sonic, Desert, and Indian) with similar
affinity (32).
Inside the cell and downstream of Smo, a large multimolecular network transduces
the Hh signal to modify the Gli proteins, zinc-finger transcription factors that mediate
Hh signaling (33). A very important protein involved in modulating the cytoplasmatic
transduction of the Hh signal is protein kinase A (PKA). The classical action of PKA in
development is a negative regulation of the PKA pathway (34). Later work identified
the PKA binding site on the human Gli1 DNA and revealed that Gli1 can be both
positively and negatively regulated by PKA (35).
Gli was originally identified as an amplified gene in a human glioma (36) and is the
analogue of the Drosophila cubitus interruptus (ci). There are three Gli proteins that
participate in the mediation, interpretation of or in the response to the Shh signal.
They reside in both the nucleus and the cytoplasm, where they are components of a
multimolecular complex that is tethered to the skeleton. Gli1 is the main activator that
acts to mediate and/or amplify the Shh response and is transcriptionally induced by
Hh signaling in all contexts examined. Gli 3 antagonizes the function of Shh-Gli1 and
Gli2 may have both activating and repressing functions (37). After translocating to the
nucleus, Gli1 promotes the expression of target genes. Target genes are Ptc, Ptc2,
Gli1 itself, as well as members of the WNT family, TGFB/BMP family, but not Shh.
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1.3 Sonic hedgehog signaling pathway in human disease
Shh signaling has been shown to regulate cell fate specification, cell proliferation and
cell survival in different target cells. Signaling can be short- and long-range, direct
and indirect, as well as concentration-dependent (reviewed in 30).
Humans or mice lacking Shh develop holoprosencephaly and cyclopia due to a
failure of separation of the lobes of the forebrain (38, 39). 
The attention drawn to the Sonic hedgehog pathway in the recent years can be
attributed to its involvement in human tumors. Inactivating mutations in the Patched
gene are responsible for the inherited cancer predisposition disorder known as Gorlin
or nevoid basal cell carcinoma syndrome (NBCCS), which comprises multiple basal
cell carcinomas (BCC) and multiple Odontogenic keratocysts (40, 41). Inactivation of
patched has been shown to be a major factor in sporadic BCC formation, with
mutations detected in between 12 and 40% of them. Inactivation of the Shh pathway
by cyclopamine has been proposed as a potential therapeutic tool in non-pregnant
adults with BCCs (42). 
The patched gene has also been implicated in the etiology of a range of other tumors
including PNETs, medulloblastoma, squamous cell carcinomas of the esophagus,
transitional cell carcinomas of the bladder, and the benign skin lesions
trichoepitheliomas. Some of these tumors express also up-regulation of other
members of the Shh pathway, such as Smo, Gli2 and Gli3. A review of diseases
associated to specific Shh pathway components is given in Table 1 (modified from
Ref. 43).
A recent review of the Sonic hedgehog pathway in human cancers (1) supports the
theory that the potential for tumorigenesis resides in stem cells.   The need for the
body to remain morphologically plastic (and therefore evolutionary fit) by retaining the
stem cells in the adult has a price – tumorigenesis.
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Hedgehog
pathway
component
Role in the pathway
Diseases and malformations
associated with increased
function ↑
Diseases and malformations
associated with decreased 
function ↓
Gli1 Regulator of Shh targets Basal cell carcinomas in
frogs and mice, brain tumors
in frogs
Gli2 Regulator of Shh targets Basal cell carcinomas in
mice
Lung, skeleton, limb, facial and
other malformations in mice
Gli3 Regulator of Shh targets Pallister-Hall syndrome, Greig
cephalopolysyndactyly syndrome
Exencephaly, limb, skeletal and
other defects in mice
Su(Fu) Regulates the state and
activity of Gli proteins.
Medulloblastoma
Smo Transducer of Hh signaling Basal cell carcinomas
Possibly brain tumors
Cyclopia and multiple effects (in
heart and gut) in mice
Ptc Hh membrane receptor
Inhibits Smoothened
Possibly holoprosencephaly Gorlin syndrome / basal cell
nevus syndrome (skeletal
defects, tumors...)
Basal cell carcinomas,
rhabdomyosarcomas,
medulloblastomas
Medulloblastomas and
rhabdomyosarcomas in mice
Tout-velu Transport of Hh Hereditary multiple exostoses
(benign bone tumors)
Cholesterol Regulation of Shh activity,
diffusion and potency
Smith-Lemli-Opitz syndrome
(growth problems, retardation
and holoprosencephaly in some
cases)
Shh Extracellular ligand Basal cell carcinomas in
mice
Holoprosencephaly
Holoprosencephaly, cyclopia and
multiple defects in many organs
in mice
Dhh Extracellular ligand Abnormal testis and peripheral
nerve sheath development in
mice
Ihh Extracellular ligand Abnormal bone formation in mice
Table 1. Highlights of diseases associated to hedgehog pathway components 
(modified from Mullor et al, Trends in Cell Biology, 2002)
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Recent in vivo and in vitro studies in vertebrates have demonstrated that the Shh
pathway, when present and activated in adult life, plays specific functions, such as: 
The hedgehog signaling regulates insulin production and increases insulin gene
transcription in INS-1 β-cells, suggesting that defective Shh signaling is implicated in
the pathogenesis of type 2 diabetes (44). 
Shh is expressed on resting and activated human peripheral CD4(+) T cells and
modulates cytokine production by these cells (45). 
Shh is also expressed by cholinergic neurons in the adult rat basal forebrain, where
acting synergistically with NGF plays a role in the development of postmitotic
cholinergic neurons, suggesting a therapeutic role in neurodegenerative disease
(46).
1.4  Shh signaling and pituitary gland development
As mentioned above, the pituitary gland is formed through the interaction of the
neural and the oral ectoderm. Recent work has begun to unravel the general
mechanisms of pituitary organ induction based on defining the obligatory interactions
between the neural and the oral ectoderm as a prerequisite for pituitary gland
formation. BMP2, BMP4, FGF and Sonic hedgehog activity are required for the
development of a definitive pouch (47).
Shh is uniformly expressed throughout the oral ectoderm, but its expression is
restricted to the Rathke’s pouch as soon as it becomes morphologically visible.
Patched is expressed at high levels in all cells of Rathke’s pouch suggesting that
cells of the nascent pituitary gland are receiving a Hedgehog signal. The Shh -/- mice
do not have a Rathke’s pouch.  In transgenic embryos over-expressing Shh inhibiting
protein, only a cystic rudiment of the pituitary gland was found (2). These results
provide strong evidence that Hedgehog signaling plays an essential role during
pituitary organogenesis.
It has been observed that overall inhibition of Shh-Gli signaling in zebrafish leads the
adenohypophysis anlage to transdifferentiate into lens. The earliest lens marker δ-
crystallin is expressed abundantly in Rathke’s pouch of chicken, suggesting a close
relationship between the cell states of the adenohypophysis anlage and the early
lens. Since the adenohypophysis is able to form lens tissue in certain mutants with
attenuated Hh signaling, it is speculated that normally Hh signaling inhibits the
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potential of lens differentiation present in the adenohypophysis anlage (48). The
crucial role of hedgehog in adenohypophysis formation in zebrafish was recently also
studied by another group, using loss- and gain- of function experiments (49) These
studies provide further evidence for the absolute necessity of Shh in pituitary
development. However, the expression of Shh in the adult pituitary has not been
examined.
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 Aim of the work
The Shh pathway is a crucial developmental pathway which is found to be active in
post-developmental life and important in human disease. Previous studies done in
pituitary development show the necessity of Shh signaling for pituitary gland
formation. 
The aims of this study were the expression of the Shh pathway members (Shh, Ptc1,
Ptc2 and Gli1) in the adult pituitary gland and the effect of the Shh pathway in the
hormone-secreting function of the normal adult pituitary. Where applicable, the
underlying mechanisms and the interactions with other known stimulants were
studied. 
At the same time, this work aimed to study the expression of Shh pathway members
in pituitary adenomas and to compare their expression between normal and
adenomatous pituitary. This could identify a possible role of Sonic hedgehog as a
pathogenetic factor in pituitary adenoma formation.
The data on Shh impact in pituitary development,  implicates this pathway with a role
in adult pituitary gland. 
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3. Methods
3.1    Equipment 
Cell culture bottles Nunc, Denmark
Cell culture incubator Cytoperm 8080, Heraeus GmbH, Hanau, 
Germany
Cell culture plates Falcon, Heidelberg, Germany
Cryostat Leica Leica Microsystems, Nussloch, Germany
Electrophoresis equipment Bio-rad Laboratories, Hercules, CA, USA
Elisa – plate reader Dynatech MR 5000, Dynatech, Denkendorf, 
Germany
Laminar flow Typ UVF 6.18 S, BDK , Luft-und
Reinraumtechnik GmbH, Genkingen,
Germany
Luminometer and fluorometer Wallac 1420, Wallac Distribution, Freiburg, 
Germany
Microscope Axioskop 2, Carl Zeiss GmbH, Jena,
Germany
Pipettes Eppendorf, Hamburg, Germany
Spectrophotometer Pharmacia, Freiburg, Germany
Table centrifuge Eppendorf, Hamburg, Germany
Water bath Köttermann Labortechnik, Uetze-Hänigsen,
Germany
22
3.2. Reagents
ABC  kit Vector Laboratories, Burlingane, CA, USA
ABC-AP  kit Vector Laboratories, Burlingane, CA, USA
Acetic acid Merck, Darmstadt, Germany
Acridine orange Sigma-Aldrich, St. Louis, MO, USA
Agar Life Technologies, Paisley, Scotland, UK
Amphotericine ICN Biomedicals, Irvine, CA, USA
Ampuwa water Frisenius, Germany
cAMP (8-CPT) Sigma-Aldrich, St. Louis, MO, USA
CRH Bachem, Bubendorf, Switzerland
Collagenase Worthington Biochemical Corporation,                                            
                                                     Lakewood, NJ, USA
Cyclopamine Toronto Research Chemicals, Toronto, Canada
Diaminobenzidine Sigma-Aldrich, St. Louis, MO, USA
DMSO Sigma-Aldrich, St. Louis, MO, USA
Dulbecco’s modified Eagle
Medium (DMEM) Gibco / Invitrogen, Carlsbad, CA, USA
Enthelan Merck, Darmstadt, Germany  
Ethidium Bromide Sigma-Aldrich, St. Louis, MO, USA 
Foetal Calf Serum Gibco / Invitrogen, Carlsbad, CA, USA
Forskolin Sigma-Aldrich, St. Louis, MO, USA
Glutamine Sigma-Aldrich, St. Louis, MO, USA
H-89 Calbiochem, San Diego, CA, USA
Hybond ECL membrane Amersham Biosciences, Bucks, UK
Hydrochlorid acid Merck, Darmstadt, Germany
Lipofectamine Invitrogen, Carlsbad, CA, USA
L-glutamine Biochrom, Berlin, Germany
Luciferin Roche, Mannheim, Germany
Lumi-light Western Blotting 
substrate Roche, Mannheim, Germany
MEM-Vitamins Biochrom, Berlin, Germany
mShh-N R & D systems, Minneapolis, MN, USA
Optimem 1 Gibco / Invitrogen, Carlsbad, CA, USA
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pAP1-Luc Stratagene, La Jolla, CA, USA
Paraformaldehyde Merck, Darmstadt, Germany
PBS Gibco / Invitrogen, Carlsbad, CA, USA
pcDNA 3,1-His Invitrogen, Carlsbad, CA, USA
pCre-Luc Clontech Laboratories, Palo Alto, CA, USA
pEGFP-C2 Clontech, Palo Alto, CA, USA
Penicillin / Streptomycin Biochrom, Berlin, Germany
Peptone ICN Pharmaceuticals, Aurora, OH, USA
Protease inhibitor cocktail Sigma-Aldrich, St. Louis, MO, USA
Qiagen Midi/Maxi Kit Qiagen, Hilden, Germany
Reporter lysis buffer Promega, Mannheim, Germany
Sodium chloride (NaCl) Roth, Karlsruhe, Germany
Sodium peroxide (NaOH) Merck, Darmstadt, Germany
Toluidin Blue Sigma-Aldrich, St. Louis, MO, USA
Transferrine Sigma-Aldrich, St. Louis, MO, USA
Triiodothyronine Henning, Berlin, Germany
Tris pure ICN Pharmaceuticals, Aurora, OH, USA
Trypsin / EDTA Biochrom AG, Berlin, Germany
Tween 20 Sigma-Aldrich, St. Louis, MO, USA
WST-1 Roche Diagnostics, Mannheim, Germany
Xylol Roth, Karlsruhe, Germany
Yeast extract ICN Pharmaceuticals, Aurora, OH, USA
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3.3    Solutions
Collagenase Mix  1000U/ml For 100 ml solution:
Collagenase: 4 g
Trypsin inhibitor: 10 mg
Hyaluronidase: 100 mg
BSA: 400 mg
Dnase: 500 µl
HDB buffer For 1 l solution:
Hepes 25mM: 5,95 g
NaCl 137mM: 8 g
KCl 5mM: 0,370 g
Na2HPO4.H2O  0,7mM: 0,120 g
Glucose 10mM: 1,982 g
Amphotericine B 25µg/ml: 10 ml
Penicillin / Streptomycin 105U/l: 10 ml
Adjust pH to 7,3 with NaOH
Store at +4°C
LB medium For 1 l solution:
Peptone: 10 g
Yeast extract: 5 g
NaCl: 5 g
NaOH 1M: 2ml
Adjust to pH 7,0
PBS  1x To prepare 1 l solution:
NaCl: 8g
KCL: 0,2g
Na2HPO4.H2O: 1,44g
KH2PO4: 0,2g
Adjust to pH 7,4
PFA  4% (paraformaldehyde) To prepare 100 ml solution:
Paraformaldehyde: 4g 
PBS: 20ml 
Ampuwa water: 80 ml
Add 1M NaOH to adjust pH 7,4
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Heat at 56°C to dissolve
Filter and cool before usage
Store at +4°C for not more than 2 days
TBS 1x (Tris Based buffer) To prepare 1 l solution:
Tris powder: 2,42 g
NaCl: 8 g
Adjust to pH 7,6
TB (Tris Buffer) To prepare 1 l solution:
Tris powder: 12,114 g
Adjust to pH 7,6
Tris-HCl  1M To prepare 1 l solution:
Tris powder: 121,42 g
Add 25% HCL to adjust pH 8,2
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3.4   Human tissues
Experiments were performed after approval of the ethics committee of the Max
Planck Institute, and informed consent was received from each patient or their
relatives. 2 normal human pituitaries (1 male and 1 female) and 55 pituitary
adenomas ( 29 males and 26 females) were included in the study.
Normal pituitary tissues were obtained from  autopsies performed 12 to 16 hours post
mortem in normal healthy subjects after accidental death. Surgically excised human
pituitary tumor tissues were obtained from consecutive unselected patients after
transsphenoidal surgery, performed in 3 neurosurgical departments in Germany and
Italy.
Tissues were placed in DMEM and transferred to our laboratory on ice within 36
hours. After washing and removing debris fibers, one aliquot was snap-frozen on dry
ice and kept at -80°C for Immunohistochemical staining (50). Snap-freezing is the
most common method for preparing tissues for immunohistochemistry procedures.
Quickly freezing tissue preserves the basic morphology and most antigens, and
produces a hard block of material that can be cut into sections for immunostaining. 
Tumors were diagnosed by clinical, biochemical, radiological and surgical findings.
IHC for hormone staining were performed to certify the anatomo-pathological
diagnosis (described later in 2.5.1). The pituitary adenomas used in this work, were
classified into acromegaly-associated pituitary tumors (ACRO; 7 cases),
prolactinomas (PROL; 3 cases), corticotropinomas (CUSH; 13 cases), TSH-secreting
adenomas (TSH; 2 cases) and clinically nonfunctioning adenomas (NFPA; 30 cases);
the later was divided after immunopathological examination into gonadotropinomas
(17 cases), null cell adenomas (11 cases), 1 silent corticotroph adenoma and 1 silent
GH/Prl secreting tumor. 
3.5 Immunohistochemistry
Immunohistochemistry (IHC) is a technique for localizing and visualizing a protein in
a tissue section by using an antibody (primary antibody) specific for the target
antigen. 
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Tissue antigens are detected by a three-stage process: the binding of the primary
antibody to its specific epitope, the binding of a biotinylated secondary antibody to
the primary antibody and the subsequent detection by a colorimetric reaction. The
secondary antibody binds the epitopes of the host animal in which the primary
antibody was raised. The enzymatic complex used is the avidin and biotinylated
horse-radish peroxidase macromolecular complex (ABC) containing the enzyme
peroxidase. Avidin is a high molecular weight glycoprotein with an extraordinarily high
affinity for the small molecular weight vitamin, biotin. The secondary antibody is
conjugated to the biotin beads, which also bind to the avidin-biotin complex. The
chromogen used to localise the peroxidase in the tissue sections was
diaminobenzidine tetrahydrochloride (DAB). DAB produces a brown precipitate which
is insoluble in alcohol and clearing agents, allowing sections to be permanently
mounted.
Another method used in this study is the ABC-AP system. The principle is the same
as above, but the enzyme used is alkaline phosphatase (AP). AP substrate produces
a more translucent reaction product than peroxidase substrates and provides
additional color choices, which are needed in double labeling (explained later in
double immunohistochemistry). The enzymatic activity of AP can be localized by
coupling a soluble product generated during the hydrolytic reaction with a “capture
reagent”. The chromogen used is vector red, which produces a red reaction that can
be seen using either brightfield or fluorescent microscopy.
Snap-frozen normal and adenomatous pituitary tissues were cut in a cryostat. 8-µm
sections were thaw-mounted onto sterile poly-L-lysine-coated slides and fixed in cold
4% phosphate-buffered paraformaldehyde (PFA). After fixation in PFA, the slides
were washed twice in PBS for 3 minutes, immersed in 70% Ethanol for 4 minutes and
then put in 96% Ethanol at +4°C for storage (as described in 51).
Antibodies
A detailed list of primary and secondary antibodies used in the study, containing the
respective hosts and dilutions used, is given in Table 2.
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Primary
antibody Source Host Dilution
Shh-N Santa Cruz Biotechnology (Santa Cruz, CA, USA) goat 1:200
Shh-N R&D systems (Minneapolis, MN, USA) goat 1:200
Ptc1 Santa Cruz Biotechnology (Santa Cruz, CA, USA) goat 1:150
Ptc2 Santa Cruz Biotechnology (Santa Cruz, CA, USA) goat 1:100
Gli1 Santa Cruz Biotechnology (Santa Cruz, CA, USA) goat 1:200
ACTH DAKO (Glostrup, Denmark) mouse 1:1000
GH Gift from Dr. C. J. Strasburger, Berlin, Germany mouse 1:800
FSH Immunotech (Marseille, France) Mouse 1:800
LH Immunotech (Marseille, France) Mouse 1:1000
Prl Immunotech (Marseille, France) Mouse 1:1000
TSH Immunotech (Marseille, France) mouse 1:800
Secondary antibody Source Host Dilution
biotinylated anti-goat
Vector Laboratories (Burlingame,
CA, USA)
horse 1:300
biotinylated anti-mouse
Vector Laboratories (Burlingame,
CA, USA)
goat 1:300
Table 2: List of Primary and secondary antibodies used in the study
3.5.1   Single Immunohistochemistry
For detecting the expression of Shh, Ptc1, Ptc2 and Gli1 at a protein level, the
specific antibodies we used in combination with the ABC complex and DAB
chromogen (as described in 52).
On the day of the experiment, the slides were briefly washed in TBS (pH 7.6) for 5
min and incubated for 30 minutes in the blocking serum. For blocking was used
serum from the same animal species in which the respective secondary antibody was
produced, in this case 10% horse serum. Afterwards the primary antibody was
applied and the slides were left overnight at +4°C. The next day, after 3 washes (5
minutes each) in TBS, the secondary antibody was applied and the slides were
incubated for 30 minutes in room temperature. The secondary antibody was
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biotinylated anti-goat, made in horse. After three further washes, the slides were
incubated with the ABC complex for 30 minutes at room temperature. The ABC
complex was prepared at least 30 minutes in advance in Tris Buffer pH 7.6 (15µl
Avidin + 15µl Biotin + 970µl TB). Then, after another three washes, the slides were
immersed in freshly prepared DAB (2 ml of 1mg/ml DAB + 33 µl of 30% hydrogen
peroxide + 98ml Tris Buffer). DAB incubation time was specific for each primary
antibody and was decided by looking at the amount of the brownish precipitate under
the microscope.
After the DAB, the slides were washed many times in TBS and counterstained with
toluidine-blue for 10 minutes. This stains the nuclei pale blue, allowing an easy view
of the tissue organization. Afterwards, the slides were briefly washed twice and
dehydrated using progressive concentrations of Ethanol (30 seconds in 70% Ethanol
+ 2 drops/100ml acetic acid 100%, 1 minute in 96% Ethanol, 1 minute in 100%
Ethanol). Slides were then fixed in rotihistol and cover-slipped with Enthelan.
For detecting the expression of pituitary hormones at a protein level (and
subsequently localizing the different pituitary cells), we used the ABC-AP kit and
Vector Red as a chromogen. The protocol is identical with the one explained above,
some substances and substrates were different. The secondary antibody was
biotinylated anti-mouse made in goat, as all primary antibodies against hormones
were produced in mouse and the blocking was performed in 10% goat serum. The
preparation of the ABC-AP complex was the same as above (15µl Reagent A + 15µl
Reagent B+ 970µl TB, made at least 30 minutes in advance). The Vector Red was
prepared according to the manufacturer’s instructions, using 2 ml of Tris-Cl solution
(100mM, pH 8,2-8,5), 500 µl Levamisol (for blocking endogenous alkaline
phosphatase activity), 1 drop of compound 1, 1 drop of compound 2 and 1 drop of
compound 3. 
3.5.2    Double Immunohistochemistry
This method facilitates the localization of two different antigens in the same tissue
section. It was performed to co-localize the expression of Shh, Ptc1, Ptc2 and Gli1 in
different hormone-producing pituitary cells. 
For this were used two different enzyme systems (peroxidase and alkaline
phosphatase) and their chromogens (DAB for ABC and Vector Red for ABC-AP),
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performing sequentially the staining of each primary antibody (as explained in 53).
The experiment was started as a  single immunohistochemical staining for detecting
one of the primary antigens (Shh, Ptc1, Ptc2 and Gli1) using ABC and DAB.
Immediately after followed the second immunohistochemical staining for detecting
the second primary antigen (one of the hormones produced by the pituitary gland),
using ABC-AP and Vector Red. Counterstaining was performed only at the end of the
second immunohistochemistry. 
3.6     Cell culture
All the cell culture work was performed under a sterile laminar flow.
3.6.1   Rat pituitary primary cell culture
The pituitary primary cell culture was obtained (as explained in 54) from adult male
Sprague-Dawley rats (180-250 g). They were kept for 5 days in our animal house in
standard conditions: 12 hours light/dark rhythm, temperature 21°C, water and
standard food. Pituitary glands were obtained after decapitation performed quickly
after CO2 narcosis. The tissue was washed throughout with HDB+ buffer [137mM
NaCl, 5mM KCl, 0.7 mM Na2HPO4, 10mM glucose, 15mM HEPES (pH 7.3)]. Sliced
fragments were inserted in a preparation buffer containing 4 g/l collagenase, 10 mg/l
DNAse II, 0.1 g/l soybean trypsin inhibitor, and 1 g/l hyaluronidase and were
enzymatically dispersed in 37°C for nearly 45 minutes. Dispersed cells were
centrifuged and resuspended in Dulbecco´s Modified Eagle´s Medium (DMEM)
supplemented with 2 mM essential vitamins, 40U/l insulin, 20 mg/l natrium selenate,
5 mg/l transferrin, 30 pM triiodothyronine (T3), 10% foetal calf serum, 2 mmol/l L-
glutamine, 2.5 ng/l Amphotericine B and 105 U/ml penicillin-streptomycin. Cell viability
was determined by fluorescence microscopy by staining with acridin orange and
ethidium bromide. Acridin orange enters the membranes of normal cells, yielding
green fluorescence in viable cells. Ethidium bromide does not pass the healthy cell
membrane and enters only in dead cells with damaged membranes, yielding a red
fluorescence. Cell viability of pituitary cells was determined as the percentage of
green cells in the total number of cells (counted in a Neubauer measuring chamber)
and was over 95%. Cells were distributed in 96-well plates and incubated at 37°C
under 5 % CO2. The stimulation was performed  48 hours after preparation.
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3.6.2   Immortalised pituitary cell lines
The immortalized cell lines used in this study were the corticotroph cell line AtT-20
and the lactosomatotroph cell line GH3 obtained from the American Type Culture
Collection (Rockville, MD, USA). The AtT-20 cell line originates from a murine ACTH-
secreting pituitary tumor (55). The GH3 cell line is originally obtained from a radiation
induced pituitary tumor in 7-month old Wistar-Furth female rats (56).
The medium used for their culture was DMEM supplemented with 10% foetal calf
serum, 2 mmol/l L-glutamine, 2.5 ng/l Amphotericin B and 105 U/ml penicillin-
streptomycin. They were kept in 75 cm2 cell culture bottles, in incubators at 37°C in
the presence of 5% CO2. When confluent, the cells were washed with PBS,
trypsinized, centrifuged at 1200g for 4 min and re-dispersed in fresh medium. They
were numbered and re-plated in new cell culture bottles and in different well-plates
according to the experiments done (as explained in 57). 
For hormone measurement and cell proliferation experiments, the cells were plated in
96-well plates. The amounts were: 2000/well AtT-20 and GH3 cells for cell
proliferation assays, 2000/well AtT-20 and 4000/well GH3 cells for hormone
measurement assays. All stimulation experiments were carried out in quadruplicates.
For transfections, the AtT-20 cells were plated in 6-well plates, at a density of
300,000 / well and all experiments were carried out in triplicates.
3.6.3     Stimulations
24 hours prior to stimulation, cells were serum-deprived to stop their growth in the G0
phase.  This step helps in putting all the cells in the same cell cycle phase, making
them so more sensitive to all further stimuli.
Stimulants
The stimulants used in the cells culture studies are as follows:
mShh-N is a recombinant mouse Sonic hedgehog amino-terminal peptide, coding the
amino acid residues 25-198 of the mouse Shh (21). A search in the NCBI databank
on Sonic hegehog mouse-rat (mus musculus – rattus norvegicus) homology maps
resulted in a full homology, so the same substance was used for experiments in
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mouse and in rat cells. The lyophilized sample was stored at –20°C. 250 µl sterile
PBS was added to the vial containing 25 µg Shh-N, giving a stock dilution 100 µg/ml.
According to the manufacturer’s instructions, the product upon reconstitution was
stored at +4°C for at most one month.
Cyclopamine is an inhibitor of the Shh pathway. The vial containing 1 mg product
was stored originally at -20°C and was reconstituted in 480 µl DMSO, yielding so a
stock dilution of 5mM. The stock dilution was aliquoted and stored in -20°C. 
CRH, human, mouse and rat corticotropin was diluted in PBS to obtain 10µl aliquots
of 200µM, which were stored at -20°C. 
Forskolin was used in hormone measurement experiments as an agonist of the PKA
(protein kinase A) pathway. It was diluted in 100% ethanol to a stock dilution of
10mM and stored at -20°C. In all experiments containing Forskolin, the same amount
of 100% ethanol was added to the other wells (containing control medium or other
stimulants).
pCPT-cAMP was used as a stronger agonist of the PKA pathway. It was dissolved in
PBS to a stock dilution of 10mM, was aliquoted and stored at –20°C.
Stimulations for RIA experiments
The cells were serum deprived for 24 hours before each experiment. Then, the
medium was removed and replaced by 100µl stimulant medium, containing
stimulants dissolved in serum deprived medium (the serum hormones interfere with
our hormone measurements). 24 hours afterwards, the experiment was stopped and
the supernatant was transferred to 0,5ml Eppendorf tubes for RIA measurements.
Stimulations for WST-1 experiments
The medium was removed from the cells in the 96-well plates and was replaced by
the stimulant medium, containing stimulants dissolved in medium containing 2% FCS
(in order to measure the effect on cell growth, the cells should proliferate and this can
happen only in the presence of serum). Another stimulation was performed after 48
hours. The experiments were stopped after 4 days, by putting WST-1 inside the wells
(explained in the WST-1 measurement).
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3.7    Hormone measurement by RIA 
Radioimmunoassay (RIA) is a highly sensitive and quantitative technique used for the
measurement of substances such as enzymes, proteins, hormones, that exist in very
low concentrations. In our study, we used RIA to measure the concentration of rat
and mouse ACTH, rat GH and rat prolactin secreted in culture by pituitary primary
cultures or stable cell lines.               
RIA uses radiolabeled Antigenes (Ag) to detect Ag:Ab reactions. The procedure
follows the basic principle of radioimmunoassay where there is competition between
a radioactive and a non-radioactive antigen for a fixed number of specific antibody
binding sites. The Ags are labeled with the I125 (iodine-125) isotope, and the
presence of Ag:Ab reactions is detected using a gamma counter. 
So the first step for starting the RIA is developing an antibody that is highly specific
for the hormone being measured. An N-terminal specific antibody against mouse and
rat ACTH was raised in rabbits using an antigen produced by the two-step
carbodiimid method (explained in 58). Standarts were purchased from Bachem
(Bubendorf, Switzerland). The rat GH and rat Prolactin antibodies were included in
the specific RIA reagent kits provided by the National Hormone and Peptide Program
(Baltimore, MD), containing the specific antigens, antiserums and standards.
A small quantity of the antibody was mixed with a certain quantity of the sample
(supernatant) containing the hormone to be measured. At the same time, a certain
amount of tracer (standard Antigen labeled with the radioactive isotope I125) was
added to the mixture. The samples were incubated 1 hour at 37°C, allowing time for
the hormone (Ag) to bind to the antibody. The mixture was prepared in such
quantities that there was not enough antibody to bind with both the labeled hormone
and with the hormone to be measured, so the natural hormone and the labeled
hormone had to compete for binding sites. The quantity of each hormone bound was
proportional to their concentration and the amount of labeled hormone (tracer) bound
to the specific antibody was inversely proportional to the concentration of the natural
hormone. After binding had reached an equilibrium, the quantity of radioactive
hormone bound to the antibody was measured in a gamma counter. As explained
above, the amount of radioactivity present in the test was inversely proportional to the
amount of hormone in the sample. 
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Quantification of the unknown free hormone in the sample was achieved by
comparing their activity with a standard curve prepared by using increasing amounts
of known concentrations of the hormone.
3.8   Cell Proliferation measurement by WST-1
WST-1 is one of the assays available for analyzing the number of viable cells by
measuring the cleavage of tetrazolium salts added to the culture medium.
The WST-1 added to the cell is converted by the mitochondrial dehydrogenases into
a dye that can be quantified by a scanning multiwell spectrophotometer (ELISA
reader). An expansion in the number of viable cells results in an increase in the
overall activity of mitochondrial dehydrogenases in the sample. This augmentation in
enzyme activity leads to an increase in the amount of the dye formed, which directly
correlates to the number of metabolically active cells in the culture.
The stimulation experiment was stopped after 96 hours by adding 10µl WST-1
reagent to each well containing 100µl of cells in medium. After 1 hour, the results
were measured in the ELISA reader at  450 nm (as explained in 59).
In each experiment, the background control was measured. This consisted of 4 wells
containing 100µl culture medium plated at the same time with the stimulation
medium, where 10µl WST-1 was added. Slight spontaneous absorbance occurs
when WST-1 is added to the medium in the absence of the cells. This background
absorbance depends on the culture medium, the incubation time and the exposure to
light (WST-1 is a light sensitive substance). The value of the background absorbance
(usually between 0,1 and 0,2 absorbance units) were subtracted from all our control
and stimulation samples. 
3.9 Western Blotting
Western blot analysis can detect one protein in a mixture of any number of proteins,
giving also information about the size of the protein. The method is dependent on the
use of a high-quality antibody directed against a desired protein. This antibody is
used as a probe to detect the protein of interest. The protein is detected through
visualization of the specific antibody. 
For the Western Blot experiment we prepared 2 x 6-well plates containing 400 000
AtT-20 cells per well. The cells were plated in normal DMEM containing 10% FCS the
next day they were about 70-80% confluent. Then, they were stimulated with Shh,
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CRH or the combination of both for 24 hours. Three wells were used for each
condition. After the stimulation time finished, the protein was extracted using a
protease inhibitor cocktail diluted 1:100 in PBS (200µl/well) and pipeting up and down
a few times with a very small (insulin) syringe.
The mixture of proteins obtained in the solution was separated using SDS-
polyacrylamide gel electrophoresis (SDS-PAGE). This separates the proteins by size.
The gel density was 10% for CRH-R1 and 15% for SHH.
Afterwards, a nitrocellulose membrane (Hybond ECL) was placed on the gel and,
using electrophoresis, the protein bands were driven onto the nitrocellulose
membrane. The negative charge was on the side of the gel and the positive charge
on the side of the nitrocellulose membrane, driving so the negatively charged
proteins over to the positively charged nitrocellulose membrane. This gives a
nitrocellulose membrane that is imprinted with the same protein bands as the gel. 
The nitrocellulose membrane was blocked for 2 hours in a solution containing 5%
milk and 0,1% TWEEN. Then, it was incubated for 1,5 hours with the primary
antibody (s. Tab. 3) diluted in 2,5% milk and 0,1% TWEEN.  The primary antibody
(the two primary antibodies we used were specific against Shh-N and CRH-R1),
sticks to the specific protein and forms an antibody-protein complex with the protein
of interest.  After the incubation with the primary antibody, the membrane was
washed 3 times, 10 minutes each in PBS containing 0,1% TWEEN.
Primary
antibody Source Host Dilution
Shh-N Santa Cruz Biotechnology (Santa Cruz, CA, USA) rabbit 1:500
CRH-R1 Santa Cruz Biotechnology (Santa Cruz, CA, USA) rabbit 1:250
Secondary
antibody Source Host Dilution
Anti-rabbit
Horseradish
peroxidase Amersham Biosciences (Bucks, UK) donkey 1:2000
Tab. 3  List of antibodies used for Western Blot analysis
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Then, the nitrocellulose membrane was incubated for 1 hour with the secondary
antibody diluted 1:2000 in  a solution containing 2,5% milk and 0,1% TWEEN. The
secondary antibody should be directed against the primary antibody. As both the
primary antibodies were made in rabbit, the secondary antibody was anti-rabbit. At
the same time, the secondary antibody was an antibody-enzyme conjugate. The
conjugated enzyme was there to allow visualization of the reaction. The secondary
antibody was conjugated to Horseradish Peroxidase. Three further washes for 10
minutes each, were then performed as explained above.
The Lumi-light Western Blotting Substrate was used to detect the enzyme and was
prepared according to the manufacturer’s instructions.
An x-ray film was put together with the membrane in an autoradiography cassette, to
detect the flash of light given off by the enzyme. After 30 seconds, the film was
removed and developed to visualise the immunoreactivity.  The bands were present
wherever there was a protein-primary antibody-secondary antibody-enzyme complex,
or, in other words, wherever the specific protein was.
3.10   Transfections
3.10.1    Plasmids
Plasmids are circular DNA molecules, nowadays very much used for studying the
control of gene expression and investigating the regulatory elements and cell
signaling.
Plasmids used in molecular biology usually contain an antibiotic resistance gene.
This helps during the transformation step (described below) for selecting only the
host bacteria resistant to a certain antibiotic. There are expression and reporter
plasmids.
The expression plasmid introduces into the cell the cDNA of the gene that we want to
overexpress, driven by a constitutively active promoter (in our case the
cytomegalovirus promoter). This increases the transcription of this gene and makes
possible the study of its effects on other genes. The expression plasmids used in this
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study are pcDNA3-mouseGli (60) (gifts from Dr. H. Sasaki, Center for developmental
biology, Riken, Kobe, Japan) and its control plasmid pcDNA 3,1-His (Invitrogen).
pcDNA3-mouseGli1 contains the full sequence of the mouse Gli1 cDNA inserted in a
pcDNA 3,1-His plasmid (Invitrogen) containing the ampicillin resistance gene. The
mouse Gli1 cDNA is here under the control of the CMV (cytomegalovirus) promoter.
For easy use terminology, this plasmid will be called mGli1 and the control plasmid
used in all the experiments will be pcDNA 3,1-His (pcDNA).
The reporter plasmids contain reporter genes sensitive to the activation status of
endogenous genes. Endogenous gene expression is monitored through creation of a
fusion gene in which the promoter of an endogenous gene is coupled to the reporter
gene, which is easier to detect. If the endogenous gene promoter is 'turned off',
neither the endogenous gene nor the reporter gene is transcribed.  Similarly, if the
promoter for the endogenous gene is activated, then the reporter gene is transcribed.
All our reporter plasmids contain the reporter luciferase.  Luciferase is an enzyme
found in the firefly beetle (Photinus pyralis) which interacts with its substrate luciferin
to produce a light emission peaking at 562nm. This emission is easily measured in a
luminometer. The luciferase activity correlates with the transcription of the gene
promoter coupled to luciferase in a certain plasmid. 
The reporter plasmids used in this study are POMC-Luc, 8 x 3’Gli-BC-Luc, 8 x
mut3’Gli-BS-Luc, AP1-Luc and Cre-Luc.
POMC-Luc contains the luciferase gene under the control of 770bp of the rat POMC
(proopiomelanocortin). These 770bp contain all the sequences necessary for the
correct in-vivo POMC expression in the mouse pituitary (18). The plasmid contains
the ampicillin resistance gene. 
8 x 3’Gli-BC-Luc and 8 x mut3’Gli-BS-Luc are a gift from Dr. H. Sasaki (Center for
developmental biology, Riken, Kobe, Japan). 8 x 3’Gli-BC-Luc contains 8 directly
repeated copies of 3’Gli-BS (unique nucleic acid sequence that binds to Gli1) bound
to the luciferase gene (61). 8 x mut3’Gli-BS-Luc is the control plasmid to be used in
all experiments: a sequence alteration within the 8xGli-BS makes the binding to Gli1
impossible, so the reporter levels are constantly off, despite  increased or reduced
Gli1 transcription.
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pAP1-Luc contains tandem repeats of the transcription factor complex AP1, the firefly
luciferase gene and the ampicillin resistance gene.
pCre-Luc is destined to monitor the activation of cAMP binding protein (CREB) and
cAMP mediated signal transduction pathways. The plasmid contains multiple copies
of the CRE-binding sequence, the firefly luciferase gene and the ampicillin resistance
gene.
Parallel control plasmid
The control plasmid used to check the transfection efficiency in all our experiments is
pEGFP-C2, encoding a variant of the Aequorea Victoria green fluorescent protein
(GFP) that has been optimized for brighter fluorescence and higher expression in
mammalian cells. The respective protein, when excited with a wave length of around
490 nm, becomes fluorescent and emits at 510 nm. This fluorescence / emission can
be measured in a fluorometer. The plasmid contains the kanamycin resistance gene.
3.10.2    Transformation
All the plasmids were received in small amounts. To obtain large quantities of
plasmid DNA, one easy way is to place the desired DNA into bacteria, grow the
bacteria, then harvest the bacteria, and isolate the DNA. The bacteria used are
treated so that they take the plasmid up into their cells. These are called competent
cells. We used competent Escherichia Coli. Because the plasmid DNA contains an
antibiotic resistance gene, the bacteria with the plasmid inside can grow also in the
presence of that specific antibiotic. The process of transformation consists of mixing
competent bacteria with plasmid DNA and then selecting bacteria containing the
plasmid using agar plates that contain an antibiotic.
For this, 10µl Competent E. Coli cells were thawed on ice and mixed with 1µl of the
transforming plasmid. The mixture was left on ice for 30 minutes, and then briefly
heat-shocked for 35-45 seconds in a +42°C waterbath. 500µl LB medium (non-
selective medium, suitable for bacterial growth) was added to permit the bacteria to
recover and express the antibiotic resistance gene and the mixture was left at 37°C
for 45 minutes. The cells were then spread on petri plates that contain a solid LB
agar medium and the specific antibiotic. The plates were incubated at 37°C overnight
to permit bacterial growth. An individual bacterium that takes up a plasmid DNA
molecule grows on the plate and gives rise to small, cell-dense colonies. All of the
39
cells in one colony are clones of the original transformant cell and so contain the
same plasmid DNA.
Identification of the transformed bacteria is facilitated by the presence of the antibiotic
resistance gene on the plasmid. Only cells that have taken up plasmid DNA and
express the antibiotic resistance gene will grow on plates containing the antibiotic.
Ampicillin, being a bacteriostatic antibiotic does not directly kill bacteria, but inhibits
their growth. Agar plates containing kanamycin were used for the pEGFP control
plasmid that expresses the kanamycin resistance gene.
For each plasmid, one single colony was picked up from the agar plate and put in
200 ml LB medium supplemented with the specific antibiotic, at 37°C to grow
overnight. The next day, the medium was centrifuged. The supernatant was
discarded and the precipitate containing bacteria and plasmid DNA was  treated
following the Qiagen Midi/Maxi Kit protocol and the manufacturer’s instructions. At
the end of the protocol, the plasmid DNA was isolated as a small pellet, which was
dissolved in 200 µl TE solution (pH 8.0). The concentration of the plasmid in this
solution was measured in a photometer.
3.10.3     Transfection
Transfection is the introduction of foreign molecules such as DNA into a recipient
eukaryotic cell. By transfecting with an expression plasmid, we overexpress a certain
gene and can study its consequences. By introducing a reporter plasmid into a cell,
one can measure the transcriptional activity of the endogenous gene linked to the
promoter. In this study were transfected AtT-20 cells. 
The day before the experiment, nearly 400 000 cells were plated in each well of a 6-
well plate, in normal DMEM containing 10% FCS. The next day, the cells were 70-
80% confluent.
To make possible the entry of the plasmid into the cell, was used the Lipofectamine
2000, a cationic lipid-based reagent designed to help the plasmid DNA enter the cell
membrane (as explained in 62). Necessary for the high efficiency of transfection and
normal entry of the plasmid DNA into the cells is the lack of serum. Therefore, a
special  medium containing all the nutrients, but no serum was used: Optimem 1.
For each well was prepared a mixture of 1,4 µg plasmid DNA, 0,6 µg pEGFP control
DNA and 10µl Lipofectamine in Optimem. The cells were left in Optimem for 6 hours.
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Afterwards, the supernatant was removed and normal DMEM without FCS was
added to the cells (some serum hormones interfere with POMC-Luc basal activity).
Stimulations (when applicable) were performed 24 hours after the beginning of the
experiment (or 18 hours after the removal of Optimem). The stimulants were added
to the cells in serum deprived medium and left for 6 hours. Afterwards, the cells were
washed once with PBS and lysed with the protein preserving lysis buffer and
scraped. The lysates were transferred into Eppendorf tubes and briefly centrifuged.
20 µl of the supernatant were plated in a nontransparent 96-well plate, the plate was
put in a Berthold Luminometer, 50µl luciferin was automatically added to each well by
the machine and the luciferase activity was measured.
In parallel, 60 µl supernatant was plated in a 96-well plate and the GFP fluorescence
was measured in a fluorometer. The program used was 285nm/315nm Fluorescence
and consists in illuminating the GFP protein inside each well with a wave length of
285nm, and measuring at the same time the emission of the fluorescent protein at
315nm. The values were corrected, so that they correspond to the 20 µl supernatant
used for the luminiscence measurement.
At the end, the luciferin values were divided by the GFP fluorescence values, to
normalize the results obtained according to the transfection efficiency in each well. All
experiments were carried out in triplicate and repeated at least three times
independently. 
All experiments where 2 plasmids (other than pEGFP) were introduced into the cells
(for example the co-transfection of mGli1 and POMC-Luc) lasted 24 hours (6 hours
on Optimem and 42 hours in Normal DMEM). 
3.11    Statistics
Hormone secretion and cell proliferation experiments were all performed in
quadruplicate (four wells having identical conditions).  The result graphs contain the
mean of 4 values for a certain condition and the standard error. 
For Hormone measurement experiments, a standard curve was created from
samples with known hormone concentration and kept as reference. For WST-1
experiments, the background values were subtracted from all the OD-450 values. To
determine the significance of our stimulants’ effects on cell proliferation and hormone
secretion, the mean values were compared by one-way ANOVA. P-values smaller
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than 0,05 were considered significant. The significance grades are marked with stars
as follows: * for p<0,05, ** for p<0,005, *** for p<0,001.
Transfection experiments were all performed in triplicate (three wells having identical
conditions). A parallel control was run inside each well. The values for each well were
corrected according to the control and the result graphs contain the mean of 3 values
for a certain condition and the standard error. The statistical significance was
determined using one-way ANOVA in combination with Scheffe’s test. P-values
smaller than 0,05 were considered significant (stars meaning explained above).     
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4.    Results
4.1 Members of the Sonic hedgehog pathway are expressed in the pituitary
gland
(Single and Double Immunohistochemistry results)
Using immunohistochemistry, the expression of Sonic hedgehog pathway members
in the normal adult pituitary was studied. 
Shh was expressed in the normal pituitary at the protein level. The stainings for Shh
were performed with 2 different antibodies and the results were similar and
consistent: cytoplasmatic staining in epithelial-type cells, evident around 5% of all the
anterior pituitary cells (Fig.4). Shh proteins were localized close to each other and in
groups.
Double IHC revealed which anterior pituitary cells express Shh. For this 2 stainings
were performed one after the other (double immunohistochemistry), first the Shh and
second the specific hormone (ACTH, GH, Prol, FSH, LH and TSH). Parallel negative
controls were run for each case. The Shh staining co-localizes 98% with that of
ACTH, showing that most Sonic hedgehog proteins produced inside the pituitary
gland originate from corticotroph cells. There were no co-localizations with
lactotrophs, gonadotrops and TSH-producing cells, while only 1-2 % of Shh cells
correlated with GH (Fig.4). 
To test whether Shh produced in corticotrophs exerts an effect on corticotroph and
other pituitary cells, we searched for the presence of Shh receptors patched 1 and
patched 2. The staining for Ptc1 and Ptc2 were evident in nearly half of the anterior
pituitary cells (Fig. 5,6). Both receptors were expressed in all the normal pituitaries
tested. 
The double IHC for Patched 1 was run in the same way as for Shh. It was evident
that the majority of Ptc1 containing cells co-localize with gonadotrophs (double stain
with LH), as well as with TSH-producing cells (Fig. 5). 
Double ICH for Patched 2 was performed as the ones above (Fig. 6). Ptc2 is mainly
localized in corticotroph cells (double staining with ACTH) and in somatotroph cells
(double staining with GH).  To a lesser degree there is co-localization with prolactin.
There was no co-staining with LH or TSH.
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Figure 4.
Sonic hedgehog protein expression in the human anterior pituitary gland. 
Shh single staining is shown separately (x20 magnification). Shh protein (brown) is marked with a
white block arrow. Double IHC staining was performed separately for each hormone (pictures in x40
magnification). The presence of the specific hormone stains the cytoplasm red and is marked with an
open arrow. The co-localization of Shh and one specific hormone in the same cell  (double staining) is
brown + red and marked with a closed arrow. The nuclei are stained in blue. 
The majority of Shh producing cells (over 98%) are corticotrophs, only 1 co-localizes with GH and
there is no co-localization with Prolactin, LH, FSH or TSH.
Shh + ACTH
Shh
Shh + Prol
Shh + TSH
Shh + GH
Shh + LH
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Figure 5.
Patched-1 protein expression in the human anterior pituitary gland. 
Ptc1 single staining is shown separately (x20 magnification). Ptc1 presence stains the cell membrane
and cytoplasm brown and is marked with a white block arrow. Double IHC staining was performed
separately for each hormone (pictures in x40 magnification). The presence of the specific hormone
stains the cytoplasm red and is marked with an open arrow. The co-localization of Ptc1 and one
specific hormone in the same cell (double staining) is brown + red and marked with a closed arrow.
The nuclei are stained in blue. 
The majority of pituitary cells possessing Ptc1 are gonadotrophs and thyreotrophs.
Ptc1 + ACTH
Ptc1 + TSHPtc1 + LH
Ptc1 + GH
Ptc1 + Prol
Ptc1
45
Figure 6.
Patched-2 protein expression in the human anterior pituitary gland. 
Ptc2 single staining is shown separately (x20 magnification). Ptc2 presence stains the cell membrane
and cytoplasm brown and is marked with a white block arrow. Double IHC staining is performed
separately for each hormone (pictures in x40 magnification). The presence of the specific hormone
stains the cytoplasm red and is marked with an open arrow. The co-localization of Ptc2 and one
specific hormone in the same cell (double staining) is brown + red and marked with a closed arrow.
The nuclei are stained in blue. The majority of pituitary cells possessing Ptc2 are corticotrophs,
sommatotrophs as well as some lactotrophs.
Ptc2+ProlPtc2 + ACTH
Ptc2 + TSH
Ptc2
Ptc2 + LH
Ptc2 + GH
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Figure 7.
Gli1 protein expression in the human anterior pituitary gland. 
Gli1 single staining is shown separately (x20 magnification). Gli1 presence stains the cell nucleus and
cytoplasm brown and is marked with a white block arrow. Double IHC staining is performed separately
for each hormone (pictures in x40 magnification). The presence of the specific hormone stains the
cytoplasm red and is marked with an open arrow. The co-localization of Gli1 and one specific hormone
in the same cell (double staining) is brown + red and marked with a closed arrow. The nuclei are
stained in blue. 
Gli1 + ACTH
Gli1 + GH
Gli1 + LH
Gli1 + Prol
Gli1 + TSH
Gli1
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Gli1 is the main transcription factor of the Shh pathway. The aim of testing for the
presence of Gli1 was to find out whether the Shh pathway is active in the pituitary
gland.
The immunohistochemistry experiments revealed that Gli1 is also present in the
human pituitary, having a partially cytoplasmic – partially nuclear staining, expected
by the fact that it translocates to the nucleus to promote the expression of target
genes (Fig. 7). 
The double immunohistochemistry finds co-expression of Gli1 with all anterior
pituitary hormones, showing that the Gli1 is present at a protein level in all hormone
secreting adenohypophysis cells.
All together, the expression of Shh, Ptc1, Ptc2 and Gli1 in human anterior pituitary
cells suggests that this pathway is active and important for the normal functioning of
the adult pituitary. Corticotrophs are Shh producing and target cells at the same time,
implying a crucial role of Shh in corticotroph cell function. 
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4.2      Sonic hedgehog increases ACTH and GH secretion in the normal rat  
pituitary
The control of pituitary hormone secretion is dependent not only on the classical 
hormone releasing factors, but also on paracrine factors such as neuropeptides, 
growth factors, cytokines, etc which have been identified in the pituitary. 
Shh is produced in corticotroph cells, but being a signaling protein it could be able to
induce effects also in distance. As also presented in 4.1, the presence of Shh
receptors and the transcription factor Gli1 indicates an active Shh pathway in anterior
pituitary hormone secreting cells. 
Therefore, it was investigated whether Shh has any role in the major function of
corticotrophs, sommatotrophs and lactotrophs, which is respectively ACTH, GH and
prolactin secretion. For this a primary culture of rat pituitary cells was prepared. The
cells were stimulated with Shh in concentrations from 0,2 to 5 µg/ml, CRH 100nM
and the combination of both Shh and CRH at maximal concentrations. The results
are presented in Fig. 8.
It results that Shh increases ACTH production in a concentration dependent manner
and the effects at 1µg/ml and at 5 g/ml are statistically significant. Shh at 5 µg/ml
increases ACTH production nearly 2,5 fold. At the same time, CRH at 100nM
increases ACTH production nearly 170% while the combination Shh 5µg/ml and CRH
100nM increases ACTH secretion over 425%, so leading to a synergistic effect.
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Figure 8.
A.  Shh stimulation of  ACTH secretion in normal rat pituitary cells
Rat pituitary cells were plated in 96 well plates at a concentration 10k/well and in 10% FCS medium.
After 2 days under basal culture conditions, they were stimulated with Shh in concentrations 0,2 –
5µg/ml using stimulation medium containing 0% foetal calf serum (FCS). Each stimulation was
performed in quadruplicates and negative controls were run in parallel. The supernatant was collected
24 hours after stimulation and ACTH secretion was measured by RIA. 
B. CRH and Shh have synergic effects in ACTH stimulation in normal rat pituitary cells
The experiment was performed in identical conditions as 5A. The cells were stimulated with Shh
5µg/ml, CRH 100 nM and the combination of both. The results are presented in increase (in
percentage) compared to the control. The absolute value of the control corresponding to 100% is 633
ng/ml.
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To examine the effects of Shh on GH and prolactin secretion on normal rat pituitary
cells, an identical experiment was performed, stimulating rat pituitary cells in primary
culture with Shh in concentrations from 0,2 to 5 µg/ml.  The results are shown in
Figures 9 and 10. 
Figure 9.
Regulation of GH secretion by Shh in normal rat pituitary cells
Fresh rat pituitary cells were plated in 96 well plates at a concentration 10k/well and in 10% FCS
medium. After 2 days in culture, they were stimulated with Shh in concentrations 0,2 – 5 µg/ml using
stimulation medium containing 0% FCS. Each stimulation was performed in quadruplicates and
negative controls were run in parallel. The supernatant was collected 24 hours after stimulation and
GH secretion was measured by RIA. 
As seen, increasing doses of Shh stimulate GH secretion in a linearly progressive
way. The effects of Shh at 1µg/ml and at 5 µg/ml are statistically significant. The
maximum concentration of Shh increases GH secretion by 220% of the control
values. 
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Figure 10.
Rat pituitary cells were plated in 96 well plates at a concentration 10k/well and in 10% FCS medium.
After 2 days in culture, they were stimulated with Shh in concentrations 0,2 – 5µg/ml using stimulation
medium containing 0% foetal calf serum (FCS). Each stimulation was performed in quadruplicates and
negative controls were run in parallel.. The supernatant was collected 24 hours after stimulation and
Prolactin secretion was measured by RIA.
A dose dependent slight increase in prolactin secretion is also seen following
stimulation with Shh (especially at 5 µg/ml) but this effect is not statistically
significant. 
The Shh localization in corticotrophs speaks for a more important role in these cells.
The Shh stimulation experiments performed in normal rat pituitary in primary culture
reveal that Shh is a secretagogue of ACTH and has a synergistic effect with CRH.
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4. 3. Sonic hedgehog effects on ACTH secretion in the AtT-20 cell line
4.3.1    Shh increases ACTH secretion in AtT-20 cells 
The increase in ACTH secretion caused by Shh in rat pituitary cells, prompted us to
study in more details the effect of Shh on hormone secretion in the AtT-20 murine
corticotroph cell line that secretes ACTH. 
For this, AtT-20 cells were plated in 96-well plates and stimulated with Shh in
concentrations from 0,2 to 5 µg/ml. 
It results that Shh at 5µg/ml induces ACTH secretion 4-5 times and this effect is
statistically very significant (Fig. 11.)
Figure 11.  
Shh stimulation of ACTH secretion in the AtT-20 corticotroph cell line
AtT-20 cells were plated in 96-well plates at a concentration of 2000 cells/well and in 10% FCS
medium. After 1 day in culture, the cells were serum-deprived for 24 hours and afterwards stimulated
in 0% FCS medium with three Shh doses from 0,2 to 5 µg/ml. The supernatant was collected 24 hours
after stimulation and ACTH secretion was measured by RIA. 
The specific Sonic hedgehog antagonist cyclopamine was also used in cell culture
experiments for hormone measurements. The original powder was diluted according
to the manufacturer’s instructions in DMSO to a stock dilution concentration of 5mM.
Cyclopamine is usually used in concentrations from 0,2 to 20 µM. Given the fact that
this is a veratrum alkaloid and potentially toxic, the toxicity of different doses in the
AtT-20 cell line was studied at the very beginning.
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For this, AtT-20 cells were plated in 96-well plates at a concentration of 2000
cells/well and in 10% medium. After 1 day in culture, the cells were serum deprived
for 24 hours and then stimulated with Cyclopamine in doses 0,2µM, 1µM, 5µM, 10
µM and 20 µM. DMSO was added to control and stimulation wells, in such amounts
that all wells included in the experiment contained the same amount of DMSO
(coming from cyclopamine stock dilution or from DMSO original tube).
After 24 hours, the cell viability was estimated using acridin orange and ethidium
bromide. Only wells having cyclopamine in concentrations lower or equal to 5µM had
the same viability as the control wells. Cyclopamine in doses 10 and 20µM was very
toxic, causing cell death.
As a result, AtT-20 cells were stimulated with cyclopamine 5µM to check its effect on
basal ACTH secretion and on Shh stimulated ACTH secretion (Fig. 12).
Cyclopamine at 5µM has no significant effect on basal  ACTH production, but it
reduces by 30% the ACTH increase by Shh 5µg/ml, and this effect is statistically
significant.  Nevertheless, the interpretation of these results should take into
consideration the limitation of not being able to use higher doses because of toxic
effects in the AtT-20 cell line (Cyclopamine  is generally used in concentrations from
5 to 20µM  in cell culture studies performed in other cell lines).
Figure 12.  
Cyclopamine effect on basal and stimulated ACTH secretion in AtT-20 cells.
AtT-20 cells were plated in 96-well plates at a concentration of 2000 cells/well and in 10% FCS
medium. After 1 day in culture, the cells were serum-deprived for 24 hours and afterwards stimulated
in 0% FCS medium with Shh 5µg/ml, Cyclopamine 5µM and the combination both. The supernatant
was collected 24 hours after stimulation and ACTH secretion was measured by RIA. 
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   4.3.2. Shh and CRH / Forskolin have synergistic effects on ACTH 
   secretion
Sonic hedgehog is produced locally in the pituitary and acts as a major ACTH
secretagogue. The mechanisms involved were studied by starting with the effect of
the co-stimulation of AtT-20 cells with Shh and CRH, the physiological stimulus for
ACTH secretion. The experiment was designed exactly as the ones in paragraph
4.3.1, using 4 different wells for each condition in 96-well plates (Fig. 13).
The co-stimulation with Shh and CRH increases ACTH secretion more than 11 times
the control values. This effect is over 200% more than the sum of the Shh and CRH
effects separately, being a synergistic effect.
Figure 13.  
Shh and CRH have synergistic effects on ACTH secretion
The experiment was performed using the same protocol as the one explained in Fig. 8. After serum
deprivation, the cells were stimulated with Shh 5µg/ml, CRH 100nM and the combination of both. After
24 hours in stimulation medium, the supernatant was collected and ACTH secretion measured by RIA.
The results are presented in increase (in percentage) compared to the control. The absolute value of
the control corresponding to 100% is 6936 ng/ml.
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The same experiment was performed using another stimulator of ACTH secretion,
forskolin. Forskolin is a phosphodiesterase inhibitor that increases the intracellular
levels of cAMP, which stimulates the PKA pathway, one of the most important
pathways by which CRH exerts its ACTH-secreting effect. 
The co-stimulation with Shh and forskolin increases ACTH secretion more than the
sum of both Shh and forskolin stimulations separately, being a synergistic effect (Fig.
14).
Figure 14.  
Shh and Forskolin have synergic effects on ACTH secretion
The experiment was performed using the same protocol as the one explained in Fig. 8. After serum
deprivation, the cells were stimulated with Shh 5µg/ml, Forskolin 5 µM and the combination of both.
After 24 hours in stimulation medium, the supernatant was collected and ACTH secretion measured by
RIA. The results are presented in increase (in percentage) compared to the control. The absolute
value of the control corresponding to 100% is 6936 ng/ml.
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4.4  Sonic hedgehog effect on hormone secretion in the GH3 cell line
4.4.1   Sonic hedgehog increases Growth Hormone secretion
The mammosomatotroph GH3 cell line secretes growth hormone and prolactin, being
so a classical model for studying the regulation of these two hormones. 
Given the fact that Sonic hedgehog is produced locally in the pituitary gland and
stimulates GH secretion in the normal rat pituitary, the effects of Shh in hormone
production by the GH3 cell line were studied as well.
For this, GH3 cells were plated in 96-well plates and stimulated with Shh in
concentrations from 0,2 to 5 µg/ml. It results that the increase in GH secretion is
linearly progressive with increasing doses of Shh and the effects are statistically
significant. Shh at maximal dose increases GH secretion more than 4,5 fold  (Fig.
15).
Figure 15.
Sonic hedgehog increases growth hormone secretion in the GH3 cell line
GH3 cells were plated in 96-well plates at a concentration of 4000 cells/well and in 10% FCS medium.
After 1 day in culture, the cells were serum-deprived for 24 hours and afterwards stimulated in 0%
FCS medium with Shh in doses from 0,2 to 5 µg/ml. The supernatant was collected 24 hours after
stimulation and GH secretion was measured by RIA. 
0
10
20
30
40
50
60
70
80
Control Shh 0,2µg/ml Shh 1µg/ml Shh 5µg/ml
G
ro
w
th
 h
or
m
on
e 
(n
g/
m
l)
    *
   **
57
4.4.2   Sonic hedgehog effect on Prolactin secretion
For studying the effect of Shh on prolactin secretion in GH3 cells, a similar
experiment to the one explained in 4.4.1 was performed. GH3 cells were plated in 96-
well plates and stimulated with Shh in concentrations from 0,2 to 5 µg/ml (Fig.16). 
Shh stimulation results in a slight increase in prolactin secretion (about 140%
increase when stimulated with Shh 5µg/ml), but this effect is not statistically
significant.
Figure 16.
Sonic hedgehog effect on Prolactin secretion in the GH3 cell line
GH3 cells were plated in 96-well plates at a concentration of 4000 cells/well and in 10% FCS medium.
After 1 day in culture, the cells were serum-deprived for 24 hours and afterwards stimulated in 0%
FCS medium with Shh in doses from 0,2 to 5 µg/ml. The supernatant was collected 24 hours after
stimulation and Prolactin secretion was measured by RIA. 
Shh stimulation results in an increase in the Prolactin secretion (about 140% increase when stimulated
with Shh 5µg/ml), but this effect is not statistically significant.
In summary, cell culture stimulation experiments show a positive role of Shh in
stimulating ACTH and GH secretion. Especially the ACTH secretion seems
remarkably increased and this effect is synergistic with CRH and Forskolin. These
results are in line with the effects observed in normal pituitary cells.
So, the Shh effect on corticotrophs seems to be more important, as it was expected
by the co-localization of Shh in these cells, meaning that the Shh signal they receive
is by themselves regenerated and quantitatively stronger as compared to the effects
in other neighboring cells.
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4.5  Sonic hedgehog and CRH cross-talk at the protein level
The results shown in 4.2 and 4.3 show a major effect of Shh as an ACTH
secretagogue, as well as a synergistic effect of Shh and CRH on ACTH secretion. In
order to identify the mechanisms of this synergism, the co-regulation of the Shh and
CRH pathways in the AtT-20 cell line was investigated. 
CRH is produced by the hypothalamus and acts as a major regulator of ACTH
secretion in corticotroph cells through the CRH-R1 receptors (Muller et al, 2001). An
upregulation of CRH-R1 by Shh could make the cells more sensitive to CRH and
explain the synergy. At the same time, as demonstrated in sections 4.1, 4.2 and
4.3.1, corticotrophs secrete and respond to Shh, indicating an autocrine or paracrine
loop. An increase of  Shh protein levels by CRH could also explain the synergism on
ACTH secretion.
 For this, AtT-20 cells were seeded in 6-well plates and treated for 24 hours with CRH
300 nM, Shh 5µg/ml and the combination of both. Afterwards, the protein lysate was
taken and used to perform a Western Blot for both Shh and CRH-R1 (Fig. 17).
Figure 17.
Shh increases CRH-R1 protein level and CRH stimulation increases Shh protein level
300000 AtT-20 cells per well were seeded in a 6-well plate in DMEM medium containing 10% FCS.
The next day, when the cells were around 70-80% confluent, they were stimulated with CRH 300nM,
Shh 5µg/ml and the combination of both. A parallel control was run and the experiment was performed
in triplicates. 24 hours after stimulation, the protein lysate was taken and frozen immediately in –80°C.
The next day, a Western Blot experiment was run, using both anti-CRH-R1 and anti-Shh antibodies.
 CRH-R1
Shh
Basal CRH
300nM
Shh
5µg/ml
CRH 300nM
+ Shh 5µg/ml
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It results that both CRH and Shh increase basal protein levels of CRH-R1, the
combination of both leads to an additive effect.
At the same time, CRH stimulation up-regulates significantly the Shh protein levels,
while Shh itself induces no changes.
The above experiment  gives data about a cross-talk between Shh and CRH
pathways in the AtT-20 cell-line. This cross-talk may be one reason for the synergy of
Shh and CRH on ACTH secretion.
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4.6     Shh pathway up-regulates POMC transcriptional activity
4.6.1    Shh increases Gli1-Luc transcription
 Gli1 is a target of itself in the ATT-20 cell line
It is known that ACTH secretion in corticotrophs is a consequence of the alternate
processing of its precursor peptide: pro-opiomelanocortin (POMC) (White and
Gibson, 1998). In order to find additional mechanisms explaining the effect of Shh on
ACTH stimulation, the effect of Shh pathway on POMC transcription was studied.
For this, AtT-20 cells were transfected with a POMC-Luc reporter plasmid,
expressing all the sequences necessary for the correct in-vivo POMC expression in
mouse pituitary. The transfected cells were stimulated with 5 µg/ml Shh, using 10%
FCS medium. A parallel negative control was run and the experiment was run in
triplicate (Fig. 18). 
As seen below Shh increases POMC-transcriptional activity over 80%.
Figure 18.  
Shh increases POMC transcriptional activity
300 000 AtT-20 cells/well were seeded in 6-well plates. 24 hours after, the medium was replaced with
transfection medium which contained the POMC-Luc plasmid and the pEGFP control plasmid (1,5µg
POMC-Luc plus 0,5µg pEGFP plasmid per well, total 2µg plasmid/well) and the transfection reagent
Lipofectamine (30µl/well) in serum-free Optimem medium. After 6 hours in transfection medium, the
cells were put in 0% FCS medium for 18 hours. The next day, the cells were stimulated with Shh 
2 µg/ml diluted in 10% FCS medium for 6 hours and the protein lysate was extracted afterwards. The
luciferin and GFP fluorescein values were respectively read in a luminometer and in a fluorometer.
The luciferase activity results were corrected according to the control GFP fluorescein values. 
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It is known that Shh effects are mediated by the activation of the transcription factor
Gli1. To check whether this mechanism is also present in the AtT-20 cell line, AtT-20
cells were transfected with the Gli1 reporter plasmid (Gli1-Luc) or the mutant Gli1
reporter plasmid (mutGli1-Luc) and stimulated with Shh (Fig. 19). The pEGFP
plasmid encoding a variant of the green fluorescent protein was used as a parallel
control. All conditions were run in triplicate.
As seen, Shh increases Gli1 transcriptional activity about 50% in the AtT-20 cell line.
This experiment verifies that Gli1 is also activated by Shh in ATT-20 cells.
Gli1-Luc + + - -
mutGli1-Luc - - + +
Shh 5µg/ml - + - +
Figure 19.
Shh increases Gli1 transcriptional activity
300 000 AtT-20 cells/well were seeded in 6-well plates. 24 hours after, the medium was replaced with
transfection medium which contained the plasmids shown above (total 2µg plasmid per well) and the
transfection reagent Lipofectamine (30µl/well) in serum-free Optimem medium. After 6 hours in
transfection medium, the cells were put in 0% FCS medium for 18 hours. The next day, the cells were
stimulated with Shh 5µg/ml for 6 hours and the protein lysate was extracted afterwards. The luciferin
and GFP fluorescein values were respectively read in a luminometer and in a fluorometer. The
luciferase activity results were corrected according to the control GFP fluorescein values. 
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It is known that Gli1 translocates to the nucleus and increases the expression of
target genes, including itself. We checked, whether Gli1 stimulates its own
expression in the AtT-20 cell line. AtT-20 cells were transfected with either the Gli1
reporter plasmid (Gli1-Luc) or the mutant Gli1 reporter plasmid (mutGli1-Luc) and
either the Gli1 expression plasmid (mGli1) or the respective control plasmid (pcDNA).
All experiments were run in triplicates. The results are presented in Figure 20.
As seen in the graph, Gli1 over-expression increases the values of the Gli1 reporter
plasmid above 100 fold. The fact that Gli1 increases its own transcription, means that
the Shh stimulation on Gli1 gets amplified over 100 times, in order to insure a greater
effect on target genes.
Gli1-Luc + + - -
mutGli1-Luc - - + +
mGli1 - + - +
pcDNA + - + -
pEGFP + + + +
Figure 20.
mGli1 increases Gli1-Luc transcription
300 000 AtT-20 cells/well were seeded in 6-well plates. 24 hours after, the medium was replaced with
transfection medium which contained the plasmids shown above (total 2µg plasmid per well) and the
transfection reagent Lipofectamine in antibiotic-free Optimem medium. After 6 hours in transfection
medium, the cells were put in 0% FCS medium. The protein lysate was taken after 24 hours. The
luciferin and GFP fluorescein values were respectively read in a luminometer and in a fluorometer.
The luciferase activity results were corrected according to the control GFP fluorescein values. 
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4.6.2. Gli1 increases POMC promoter transcription
In this work has been shown so far that Shh stimulates both Gli1 transcriptional
activity and POMC transcription. In order to further elucidate the  mechanisms
involved in the strong ACTH stimulating effects of Sonic hedgehog in the AtT-20 cell
line and corticotroph cells, the effect of  Gli1 on POMC transcription was studied.
For this, AtT-20 cells were transfected with the POMC reporter plasmid (containing
POMC-promoter linked to the luciferase gene) and either the Gli1 expression plasmid
(mGli1) or the respective control plasmid (pcDNA). The pEGFP plasmid was used as
a parallel transfection efficiency control. All experiments were run in triplicates (Fig.
21).
Gli1 over-expression increases the POMC-Luc values about 6 times compared to the
control. These results reveal that a new transcription factor : Gli1 can activate POMC.
This transcription factor mediates the Shh up-regulating effects on POMC
transcription and consequently on ACTH secretion. 
Figure 21.
mGli1 increases POMC transcriptional actvity
300 000 AtT-20 cells/well were seeded in 6-well plates and transfected according to a protocol similar
to the one explained in Fig.18. The transfection medium contained the plasmids shown above (total
2µg plasmid per well) and the transfection reagent Lipofectamine in antibiotic-free Optimem medium.
The cells were left 6 hours in Optimem, afterwards 42 hours in 0% FCS medium and the protein lysate
was taken 48 hours after the start of the experiment. The luciferase activity results were corrected
according to the GFP control fluorescein values. 
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4.7 Sonic hedgehog and CRH pathway cross-talk at the transcription level
4.7.1 Gli1 is upregulated by CRH and cAMP
The Gli1-induced increase of POMC transcription (4.6.2), the well known CRH
increase of POMC transcription (63), the synergism of Shh and CRH on ACTH
secretion (4.2 and 4.3.2) and the cross-talk between Shh and CRH pathways at a
protein level (4.5), prompted us to study a possible cross-talk of these two pathways
on the regulation of POMC transcription.
To start with, the effect of CRH on Gli1 gene transcription was studied . AtT-20 cells
were plated in 6 well-plates, transfected with the Gli1 reporter plasmid and then
stimulated with CRH 300nM (Fig. 22). As seen, CRH increases Gli1-Luc
transcriptional activity about 2,6 times.
Figure 22.
CRH increases Gli1 transcriptional activity
300 000 AtT-20 cells/well were seeded in 6-well plates and transfected according to a protocol similar
to the one explained in Fig.18. The transfection medium contained the Gli1 reporter plasmid
(1,5µg/well), the pEGFP control plasmid (0,5µg/well) and the transfection reagent Lipofectamine
(30µl/well) in antibiotic-free Optimem medium. The cells were left 6 hours in Optimem, afterwards put
in 0% FCS medium for 18 hours and then stimulated with 300nM CRH. Three wells were used for
each specific condition. After 6 hours in stimulation medium, the protein lysate was obtained and the
luciferin and GFP fluorescein results were read. The luciferase activity results were corrected
according to the respective GFP fluorescein values.
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Cyclic AMP (cAMP) is a crucial mediator in both CRH and Shh pathways. It has a
well-known strong effect on POMC transcription activated by the CRH pathway. At
the same time, is a important regulator of the Shh pathway, known to exert positive or
negative effects in mammalian cells (see 1.2). 
The effect of cAMP on Gli1 transcriptional activity was studied in order to further
elucidate a possible cross-talk between Shh and CRH pathways on POMC
regulation. AtT-20 cells were plated in 6 well-plates, transfected with the Gli1 reporter
plasmid and then stimulated with cAMP (Fig. 23/A). The effect of cAMP on POMC
was tested in parallel in a similar experiment (Fig. 23/B). 
As seen in the graph, cAMP stimulation increases Gli1 transcriptional activity about 3
times. The parallel increase of POMC transcription is shown as a positive control of
the cAMP effects. 
Figure 23.
cAMP increases Gli-Luc (A) and POMC-Luc(B) transcriptional activity
A. The experiment was performed identically as the one explained in Fig. 22. The AtT-20 transfected
cells were stimulated with 500µM cAMP. 
B. The experiment is identical to the one explained in Fig. 23/A. The AtT-20 cells were transfected for
6 hours in Optimem medium containing the POMC reporter plasmid (1,5µg/well), the pEGFP
control plasmid (0,5Mg/well) and the transfection reagent Lipofectamine (30µl/well). Afterwards,
they were put in 0% FCS medium for 18 hours and then stimulated with 500µM cAMP for 6 hours.
A. B.
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4.7.2   Gli1 increases AP-1 and Cre transcriptional activity
This part of the study aims to further elucidate the mechanisms of Shh / Gli1
stimulation of POMC and the cross-talk between Shh and CRH pathways. The effect
of Gli1 on two transcription factors known to be upstream and up-regulate POMC:
CREB and AP1 (see 1.1.2) was studied. 
For this AtT-20 cells were transfected with either the Gli1 expression plasmid or the
respective control and either the Cre reporter plasmid or the AP-1 reporter plasmid.
The experiment contained triplicates for each specific condition and the pEGFP
control plasmid was co-transfected in all the wells (Fig. 24). 
As seen, mGli1 increases both AP-1 and Cre transcriptional activity in a statistically
significant way (respectively, p<0,05 and p=0,001). Therefore, Gli1 can act upstream
of AP-1 and CREB.
Figure 24.
A. mGli1 increases AP1 transcriptional activity
The experiment was performed using an identical protocol as the one explained in Fig. 18. The cells
were transfected with AP1-Luc, mGli1 or pcDNA and the control plasmid pEGFP. The protein lysate
was taken 48 hours after the start of the experiment and the luciferase activity values were corrected
according to the relevant GFP fluorescence values. 
B. mGli1 increases Cre-Luc transcriptional activity
The experiment was performed identically as the one explained in Fig. 16A. The cells were transfected
with Cre-Luc, mGli1 or pcDNA and the control plasmid pEGFP and the luciferase activity values were
corrected according to the relevant GFP fluorescence values.
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4.8     Sonic hedgehog pathway members are downregulated in pituitary tumors
The experiments presented in 4.1 - 4.7 elucidate an important role for Shh pathway in
normal pituitary. Previous work done in development has shown that Shh plays a role
in the differentiation and growth of Rathke’s pouch (2). Therefore, it was interesting to
study the members of the Shh pathway in different human pituitary tumors.
For this, an extensive screening of 56 tumors was performed. At the beginning, each
tumor was screened for the hormone content analysis (single immunohistochemistry
for detecting the expression of pituitary hormones at a protein level). This determined
the cell type each tumor possessed. Tumors that contained many different cell types,
indicating that part of normal pituitary is resected adjacent to the tumor tissue, were
excluded from this study.
The screening of tumors for Shh, Ptc1 and Gli1 was performed by
Immunohistochemistry. The 55 pituitary adenomas included in the study were
classified into acromegaly-associated pituitary tumors (ACRO; 7 cases),
corticotropinomas (CUSH; 13 cases), prolactinomas (PROL; 3 cases), TSH-secreting
adenomas (TSH; 2 cases) and clinically nonfunctioning adenomas (NFPA; 30 cases);
the later was divided after immunopathological examination into gonadotropinomas
(17 cases), null cell adenomas (11 cases), 1 silent corticotroph adenoma and 1 silent
GH/Prl secreting tumor. Each IHC experiment was run with one primary antigen only
and included in parallel 15 tumor slides and one normal pituitary slide used as
control. The IHC results were evaluated by two different persons and then compared. 
The intensity of the staining was classified in three different grades: 0, 1 and 2.  
0 stands for no immunoreactivity, 1 stands for less than 1% of pituitary cells positive
and 2 means more than 1% of pituitary cells positive. An extra classification was
added for immunoreactivity in the connective tissue. It was marked with x and, if
present, added to the main classification grade. This classification was decided by
the fact that the immunoreactivity for each of the three proteins studied, especially
Shh and Gli1 was very low compared to normal pituitary. 
Details of each tumor, including patient data, clinical diagnosis and grade, hormone
IHC characteristics and all immunoreactivity results for Shh, Ptc1 and Gli1 are given
in Tab. 4. 
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Patient
number Age Sex
Clinical
Diagnosis Hormone IHC Characteristics Grade Shh ir Ptc1 ir Gli1 ir
1 31 M ACRO GH II 0 1 0
2 28 F ACRO GH II 0 1 + x 0
3 51 F ACRO GH III 0 1 0
4 24 M ACRO GH II 2 2 2
5 67 M ACRO GH III 0 1 0
6 50 M ACRO GH / Prl II 0 0 0
7 69 M ACRO / PROL GH / Prl III 0 0 + x 0
8 33 M CUSH ACTH II 0 0 0
9 32 F CUSH ACTH II 0 1 0
10 18 F CUSH ACTH II 0 0 0
11 36 F CUSH ACTH III 0 0 0
12 45 F CUSH ACTH III 0 0 0
13 14 M CUSH ACTH III 0 0 0
14 40 F CUSH ACTH III 0 0 0
15 31 M CUSH ACTH II 0 0 0
16 52 F CUSH ACTH II 0 0 0
17 59 M CUSH ACTH III 0 0 0
18 63 F CUSH ACTH III 0 0 + x 0
19 20 F CUSH ACTH II 0 1 0
20 47 F CUSH ACTH II 0 1 + x 0
21 50 F NFPA ACTH III 0 0 + x 0 + x
22 49 M NFPA FSH III 0 1 0
23 29 F NFPA FSH III 0 0 + x 0
24 64 M NFPA FSH III 0 0 0
25 52 F NFPA FSH III 0 1 0
26 76 M NFPA FSH III 0 + x 0 + x 0 + x
27 34 M NFPA FSH II 0 0 + x 1
28 61 F NFPA FSH III 0 0 + x 0
29 35 M NFPA FSH II 0 0 0
30 52 M NFPA FSH III 0 1 0
31 64 M NFPA FSH III 0 0 0
32 36 F NFPA FSH / LH II 0 2 0
33 42 M NFPA FSH / LH III 0 0 + x 0 + x
34 55 M NFPA FSH / LH II 0 0 + x 0
35 28 F NFPA GH / Prl II 1 1 0
36 28 M NFPA LH II 0 1 0
37 53 M NFPA LH III 0 1 0
38 59 M NFPA LH II 0 1 0
39 60 M NFPA LH III 0 2 0
40 51 F NFPA None III 0 0 0
41 49 M NFPA None II 0 1 0
42 68 M NFPA None III 0 1 0
43 59 F NFPA None III 0 + x 1 0
44 54 M NFPA None III 0 + x 1 0
45 47 F NFPA None III 0 2 x
46 47 F NFPA None II 1 + x 1 + x 0 + x
47 57 M NFPA None II 0 1 x
48 61 M NFPA None III 0 + x 0 + x 0
49 52 F NFPA None II 0 2 0
50 52 F NFPA None II 0 0 + x 0
51 18 F PROL Prl II 0 0 0
52 26 F PROL Prl II 1 0 0
53 41 M PROL Prl / GH II 0 0 0
54 56 M TSH TSH / α-subunit II 2 2 1 + x
55 31 F TSH / ACRO TSH / α-subunit III 0 0 0
Table 4. 
Characteristics of 55 tumors used in the study and their IHC results to Shh, Ptc1 and Gli1. 
NFPA = non functioning pituitary adenoma,  ACRO = acromegaly,  PROL = prolactinoma, 
TSH = TSH-oma, ir = immunoreactivity, 0 = no immunoreactivity, 1= <1% of cells positive, 
2 = >1% of cells positive, x = immunoreactivity in the fibres.
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Patient details, clinical diagnosis and tumor grade were obtained from the
neurosurgical departments where the tumor resection was performed. Hormone
expression analysis and Shh, Ptc1 and Gli1 immunoreactivity were performed in our
department.
The IHC staining of different tumors for Shh, Ptc1 and Gli1 compared to the normal
pituitary as control, are shown respectively in Figures 25, 26 and 27. 
Figure 25. 
Shh protein expression in the anterior pituitary gland and in different pituitary adenomas, detected by
immunohistochemistry. 
Shh expression stains the cell cytoplasm brown and is marked with an arrow. The normal pituitary
picture is shown in x20 magnification and the pituitary adenoma pictures are shown in x40
magnification. A marked reduction of Shh staining is seen in pituitary adenomas as compared to the
normal pituitary.
NP       normal pituitary
ACRO  acromegaly
CUSH  cushing
NFPA   non-funtioning
            pituitary adenoma
ACRO
CUSH NFPA
NP
70
Figure 26.  Ptc1 staining in different pituitary adenomas compared to the normal pituitary as control
Ptc1 protein (brown) is marked with an arrow. The normal pituitary picture is shown in x20
magnification and the pituitary adenoma pictures are shown in x40 magnification. A reduction in Ptc1
expression as compared to normal pituitary is noticeable in all pituitary adenomas.
Figure 27.  Gli1 staining in different pituitary adenomas compared to the normal pituitary as control 
Gli1 protein (brown) is marked with an arrow. The normal pituitary picture is shown in x20
magnification and the pituitary adenoma pictures are shown in x40 magnification. A significant
reduction of Gli1 expression as compared to normal pituitary is noticeable in all pituitary adenomas.
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The immunohistochemistry results shown above present a marked reduction of Shh
and Gli1 in pituitary tumors as compared to the normal pituitary, meaning a
downregulation of the Shh pathway in pituitary tumors.
Another table containing the Shh, Ptc1 and Gli1 expression in hormone-secreting
cells of different tumors, summarizes the evaluation of the IHC results presented in
Tab. 3. These results are given in percentages of tumors having different intensities
of expression (Tab. 5).
Sonic hedgehog
grade
Patched-1
grade
Gli-1
grade
0 1 2 0 1 2 0 1 2
Cushing (%) 100 0 0 77 23 0 100 0 0
Acromegaly (%) 88 0 12 38 50 12 88 0 12
Non-functioning tumor (%) 93 7 0 43 43 13 97 3 0
Prolactinoma (%) 80 20 0 100 0 0 100 0 0
TSH-secreting tumor (%) 50 0 50 50 0 50 50 50 0
Table 5.
Shh, Ptc1 and Gli1 expression in pituitary adenomas.
NFPA = non functioning pituitary adenoma,  ACRO = acromegaly,  PROL = prolactinoma, 
TSH = TSH-oma, ir = immunoreactivity, 0 = no immunoreactivity, 1= <1% of cells positive, 
2 = >1% of cells positive, x = immunoreactivity in the fibres.
The table presents the percentage of Cushing, Acromegaly, Prolacting secreeting, TSH secreeting
and non-functioning tumors that contain IHC staining for Shh, Ptc1 and Gli1 in different levels (nothing,
less than1% or more than 1%).
No Shh and Gli1 expression was found in 100% of Cushing tumors studied, indicating a
downregulation of the Shh pathway.
All results presented in 4.8 show a reduction of Shh pathway members (especially
Shh and Gli1) in pituitary adenomas. Given the fact that corticotrophs normally
produce Shh themselves, the disappearance of Shh in all Cushing tumors studied is
certainly to be considered further. 
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4.9      Sonic hedgehog effect on cell proliferation in the AtT-20 and GH3 cell  
lines
The obvious reduction of Shh and Gli1 expression in all pituitary adenomas as
compared to the normal pituitary suggests that Shh plays a role in pituitary adenoma
development. Therefore, the effect of Shh on cell proliferation in the corticotroph
pituitary cell line AtT-20 and in the mamosommatotroph pituitary cell line GH3 was
studied. 
4.9.1     Shh reduces cell proliferation in the AtT-20 cell line
AtT-20 cells were seeded in 96-well plates, serum deprived and stimulated every 48
hours with Shh in doses from 0,5 to 5 µg/ml. 96 hours after the start of stimulation,
the cell number in each well was measured by the WST-1 method (Fig. 28).
It results that Shh decreases cell proliferation, up to 40% and this result is statistically
significant.
Figure 28.
Shh reduces AtT-20 cell proliferation
AtT-20 cells were seeded in 96-well plates, putting 2000 cells per well in 10% FCS medium. The next
day, they were serum deprived for 24 hours and afterwards stimulated with different doses of Shh
diluted in stimulation medium containing 2% FCS. The experiment was run in quadruplicates, using as
stimulation control cells in medium only and medium only without cells. Due to the potential
degradation at 37°C, the stimulant was added after 48 hours. After 4 days in stimulation medium,
WST-1 was added and 45 minutes afterwards, the results were measured in the Elisa reader, using a
wave-length of 450 nm. The OD values were corrected after substracting the values of medium
without cells.
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To test the effect of cyclopamine on this Shh induced decrease of AtT-20 cell
proliferation, we performed an experiment identical to the one explained in Fig. 24,
but stimulating with the maximal dose of Shh and the combination of Shh plus
Cyclopamine (maximal non toxic dose as explained in 4.3.1 is 5µM). The results are
presented in Fig. 29.
Cyclopamine at 5µM partially reverses the Shh induced decrease in AtT-20 cell
proliferation and this result is statistically significant. The use of higher doses of
Cyclopamine was not possible because of cytotoxicity in the AtT-20 cell line. 
Figure 29.
Cyclopamine reverses the Shh induced decrease in AtT-20 cell proliferation
The experiment was performed as the one explained in Fig. 27. The only difference consists in adding
to the control and Shh only containing wells the same dose of DMSO present in the Cyclopamine
treated wells. 96 hours after the start of the stimulation, WST-1 was added to each well and 45
minutes after the results were read in the Elisa reader.
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4.9.2  Shh has no impact on GH3 cell proliferation
For studying the effect of Shh on GH3 cell proliferation, GH3 cells were seeded in 96-
well plates, serum deprived for 24 hours and then stimulated with Shh in doses from
0,2 to 5 µg/ml, cyclopamine 5µM (maximal non-toxic dose for GH3 cells as well,
identified in the same way as explained in 4.3.1 for ATT-20 cells) and the
combination of maximal doses of Shh and Cyclopamine (Fig. 30).
As seen in the graph, Shh at different doses, Cyclopamine in the maximal non-toxic
dose and the combination of both have no statistically significant effect on GH3 cell
proliferation.
Figure 30.
Shh has no effect on GH3 cell proliferation
GH3 cells were seeded in 96-well plates, putting 2000 cells per well in 10% FCS medium. The next
day, they were serum deprived for 24 hours and afterwards stimulated with different doses of Shh,
Cyclopamine and the combinaiton of Shh and cyclopamine, diluted in stimulation medium containing
2% FCS. The experiment was run in quadruplicates, using as stimulation control cells in medium only
and medium only without cells. Due to the degradation at 37°C, the stimulants were added after 48
hours. After 4 days in stimulation medium, WST-1 was added and 60 minutes afterwards, the results
were measured in the Elisa reader, using a wave-length of 450 nm. The OD values were corrected
after substracting the values of medium without cells.
  
           
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0,4
Control Shh 0,2 µg/ml Shh 1 µg/ml Shh 5 µg/ml Cyclop. 5µM Cycl. 1µM +
Shh 1 µg/ml
W
ST
-1
 (O
D
=4
50
nm
)
75
5.     Discussion
Advances in defining the biological cascades behind pituitary gland development
have shed light on the importance of the cross-talk between signaling molecules and
differentiating factors as well as on cell-to-cell communication (reviewed in 4). Recent
studies have revealed that differentiating factors needed for normal pituitary
development like retinoic acid and BMP4 continue to have a very important role in
pituitary physiology and tumorigenesis (18, 19). The present thesis demonstrates that
another differentiating factor: Shh, also plays an important role in the cross-talk
mechanisms that regulate the adult pituitary.
In the last decades, it has been shown that the pituitary gland, in addition to the
classical hormones, also produces numerous polypeptide growth factors, cytokines,
and neuropeptides. Expression of the corresponding receptors on pituitary cells
enables these factors to influence growth and function of the pituitary by auto- or
paracrine mechanisms. This evidence reveals that the intrinsic intercellular
communication network seems to be involved in the control of pituitary homeostasis,
in addition to the classical endocrine feed-back regulation (reviewed in 64 and 65).
Auto-/paracrine mechanisms have an impact on the normal pituitary function and
their disturbance may also play a crucial role in pituitary tumor progression.
Shh is absolutely required for early stages of normal pituitary development, but its
role in the pituitary has not been taken further.
This work studied the expression and function of the Shh pathway in the adult
pituitary and pituitary adenomas. Shh, its receptors Ptc1 and Ptc2 and the
transcription factor of the Shh pathway Gli1 are all expressed in the human pituitary.
Shh is produced in the corticotrophs, while each of other types of pituitary hormone
secreting cells possesses one of the receptors and the transcription factor Gli1.  At
the same time, acting as an auto- or paracrine factor, Shh induces ACTH and GH
hormone production. Especially the effect on ACTH is quantitatively very important
and seems to be induced through signal transduction mechanisms that cross-react
with the CRH pathway.
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At the same time, comparative expression studies reveal a remarkable reduction of
Shh signaling in pituitary tumors. Although present in normal corticotrophs, Shh is
found in none of Cushing tumors studied. The absence of the Gli1 transcription factor
also emphasizes that there is no Shh signaling. 
In ACTH producing cell line models, Shh reduces cell proliferation by 50%.
Therefore, Shh helps in maintaining corticotrophs in a non-proliferative state. In the
absence of Shh, corticotrophs proliferate more and this results in ACTH-producing
adenoma formation. 
Expression of Shh pathway members in the pituitary gland
Shh is expressed in the adenohypophysis at the protein level. Double-staining
methods reveal that it is localized in the pituitary corticotrophs. Being a secreted
protein, Shh is able to diffuse and induce effects in other neighboring cells. So, the
protein produced in corticotrophs, is theoretically available for other cells, where it
may also have important functions.
The finding of both Patched receptors (Ptc1 and Ptc2) and of the transcription factor
Gli1 in the pituitary gland, helps to define a hypothesis for the role of this pathway.
Ptc1 is co-localized in gonadotrophs and in thyrotrophs, while Ptc2 is co-localized in
corticotrophs, somatotrophs and to a lesser degree in lactotrophs. The Ptc1 and Ptc2
receptors keep also in the pituitary gland the general rule of not overlapping with
each other: they are expressed in different cell types. The transcription factor Gli1
was also found in all types of hormone-producing pituitary cells. Our findings suggest
an active Shh pathway in the adenohypophysis. It is clear that Shh coming from
corticotrophs, binds to receptors Ptc1 and Ptc2 and induces effects in all  types of
hormone-secreting  cells. Therefore, the Shh pathway could contribute to co-ordinate
the regulation of different cell types in the pituitary gland.
Corticotrophs also possess the Patched-2 receptor and the transcription factor Gli1.
Patched-2 is known to be co-expressed with Shh also in other tissues (31). The
above results show that corticotrophs produce Shh and also respond to Shh at the
same time. Apparently, Shh acts in an autocrine way to maintain an active signal
transduction pathway in ACTH-secreting cells.
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Corticotrophs originate directly from one branch of Rathke’s pouch stem cells in the
early stages of pituitary development. Other adenohypophysis cells derive from a
second branch, having more gene markers in common with each other than with the
corticotrophs (66). So one may speculate that corticotrophs are needed at early
stages in the pituitary gland development. They produce Shh, which becomes later
through paracrine mechanisms available to other pituitary hormone-producing cells,
and maintains an active Shh signaling pathway in the normal pituitary gland.
Hormone secretion from the rat pituitary cells in primary culture
It is known that normal pituitary cells do not proliferate, their main physiological
activity is specific hormone secretion in response to different stimuli. Therefore, after
the first evidence for an active Shh pathway in the pituitary gland, the most important
question raised was whether there was an impact on hormone production. 
The stimulation experiments done in the rat pituitary primary culture show that Shh
increases ACTH production even more than CRH.  Given the fact that CRH is the
most important physiological stimulus of increasing ACTH basal secreting levels, this
finding is very important and intriguing. At the same time, CRH and Shh have
synergistic effects on ACTH secretion. The combination of both of them is a very
potent stimulus of ACTH secretion in the pituitary primary culture. 
Shh was also found to increase over 2 fold the GH secretion in the pituitary primary
culture. This effect does not seem as high as the ACTH increase in corticotrophs, but
it seems proportionate to the amount of Gli1 presence found in the pituitary by IHC
(or to the percentage of cells containing an active Shh pathway). The transcription
factor Gli1 is expressed in over 50% of corticotrophs, but not in many somatotrophs
and even in less lactotrophs. Shh induces an increase in prolactin secretion, but this
effect is not statistically significant. So the Shh pathway seems to be more active in
the corticotroph cells.
Nevertheless, Gli1 expression in at least part of other anterior pituitary epithelial cell
types, indicates a possible Shh physiological effect. Even if this would not be direct
hormone secretion, there could be synergy with other stimuli, release of other
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paracrine factors, etc. This is why these results seem to open other possibilities and
another line of research in the challenging pituitary research field.
Shh effects on ACTH secretion in the ATT-20 cell line
The AtT-20 murine corticotroph cell line (54) is one of the most studied pituitary cell
lines, that has been used since decades as a model to  understand the physiology
and pathology of corticotrophs action. This cell line  responds to CRH and is a
classical model for studying the effects of stimulants that induce ACTH secretion
above basal levels.  The effects of classical ACTH secretagogues in this cell line are
well known: CRH increases up to two-fold ACTH secretion (67), forskolin by
activating adenylate cyclase activates also the CRH pathway, while vasopressin has
a little significant effect only when stimulated in the absence of serum  (68).
The effect of Shh in the AtT-20 cell line is even higher than the one in the pituitary
primary culture (expected, as the cell line contains 100% corticotrophs. A 4-5 times
increase in ACTH secretion and also a marked synergy with CRH and Forskolin was
observed. While CRH increases ACTH secretion less than 2 times, the combination
Shh plus CRH induces an 11 fold increase.  This is one of the most potent stimuli in
increasing ACTH secretion in the AtT-20 cell line, which contains already persistently
high ACTH basal levels.
ACTH increase caused by Shh is partially reversible by its specific antagonist
Cyclopamine. This partial effect may be caused by the modest doses of Cyclopamine
used (higher doses are toxic for the cells). Nevertheless, it is interesting that
cyclopamine does not have any statistically significant effect on ACTH basal
secretion. This suggests that Shh would not play a role in maintaining the basal
ACTH secretion in this cell line.
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Shh effects in the GH3 cell line
The mammosomatotroph GH3 cell line (55) is another accepted model for studying
GH and Prolactin secretion. The effects of Shh here were quite similar to the ones in
the pituitary primary culture: a more than 4-fold increase in GH production and no
statistically significant effect on Prolactin secretion.
Shh increases CRH-R1 protein levels in synergy with CRH
CRH induces a major increase in Shh protein levels in the AtT-20 cell line
This work also aimed to find out the mechanism of the stimulatory effect of Shh on
ACTH and its synergy with CRH. 
CRH pathway becomes active in corticotrophs after the binding of CRH to its
membrane receptor CRH receptor 1 (CRH-R1) (69). Shh increases CRH-R1 protein
basal levels and this effect is synergic with CRH. So one may speculate that Shh is
needed in corticotrophs to help in the response to CRH.
One interesting result is the finding that CRH induces a great increase in Shh protein
levels. This makes Shh one of the few known target genes of CRH. There is a cross-
talk between CRH and Shh pathways at the protein level. One could speculate that
Shh helps to increase the response to CRH from the hypothalamus, while CRH itself
is important in maintaining and increasing the Shh levels in the corticotrophs.
Knowing that corticotrophs are the only local source of Shh in the adenohypophysis,
this result becomes more interesting. Knowing that Shh pathway is active and may
have functions in other pituitary cells, it can be speculated that CRH may be an
important factor not only for the maintenance of ACTH secretion, but also for the
maintenance and coordination of other physiological parameters and functions of the
anterior pituitary. 
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Transfection results in the AtT-20 cell-line 
(Gli1 expression and reporter plasmid results)
Gli1 is the transcription factor that mediates the effects of the Shh pathway. It
becomes activated in the cytoplasm and then translocates to the nucleus to induce
the transcription of target genes.  It is generally known that among the genes induced
is also Gli1 itself.  Our experiments in the AtT-20 cell line, verified that this rule is also
present in the AtT-20 cell line. 
Shh as well as the Gli1 expression plasmid increase Gli1 transcriptional activity. The
increase caused by the Gli1 expression plasmid is over 100 fold.  The conclusion is
that Shh signals inducing the Shh pathway, activate Gli1, which by increasing its own
transcription, induces a quantitatively much higher response of target genes. So, not
much Shh is apparently required, as its signaling cascade amplifies itself. At the
same time, Gli1 increases POMC promoter transcription about 6-times compared to
the control.  
It is known that CRH induces POMC promoter transcription mainly through the PKA
pathway and the most important downstream transcription factors are Cre and AP-1.
Trying to reveal possible mechanisms of Shh-CRH synergy, the effect of the CRH
pathway on Gli1 transcription was studied. CRH and cAMP-CPT (the most potent
stimulator of PKA) both increase the Gli1 transcriptional activity. The stimulation
obtained shows that the CRH and PKA act upstream to Gli1.
At the same time was studied the effect of Gli1 on Cre and AP-1 reporter plasmids,
revealing that Gli1 increases the transcription of both of them. So, Gli1 can act
upstream to CREB and AP-1.  However, CREB can be directly phosphorilated by
PKA. Therefore, CREB and Gli1 can act in parallel. 
It seems that there is a multiple cross-talk between Shh and CRH pathways at the
transcriptional level. These pathways seem to regulate each other mutually at
different levels, aiming in any case to obtain a well-controlled and high increase of
ACTH secretion. 
A proposed mechanism explaining the synergic effect of CRH and Shh on ACTH
secretion is given in Fig. 31.
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Figure 31.
Cross-talk between Shh and CRH pathways
Shh binds to its receptor complex Ptc-Smo and then activates the transcription factor Gli1. CRH
binds to the receptor CRH-R1 and acting through the transcription factors AP1 and CRE, increases
POMC promoter transcription. The results of this thesis reveal that Gli1 is up-regulated by CRH and
PKA and increases POMC promoter transcriptional activity, acting upstream to CREB and AP1.
Gli1
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Shh pathway is downregulated in pituitary tumors
The screening of 55 pituitary tumors for the protein levels of Shh pathway members,
shows a marked reduction of Shh, Ptc1 and Gli1 in all pituitary tumors. 
Ptc1 is reduced to a lesser extent. Ptc1 is a negative transducer of Shh signaling, so
it may be present in the cell even when the pathway is inactive. On the other hand,
Ptc is a known target of Gli1, so it makes sense to have a reduction in Ptc1 signaling
when the Gli1 levels are also low or negative.
The reduced Shh and Gli1 expression in Prolactinomas, Acromegaly, Non-
functioning pituitary tumors and in TSH-secreting pituitary tumors may be compatible
with the fact that these tumors do not contain corticotroph cells, essential for
secreting Shh. A few rare cases where Shh or Gli1 may be present, may reflect a
mixture with some normal pituitary tissue during tumor removing surgery.
Nevertheless, the impact of this Shh pathway downregulation in all these tumors is
not known. Whether there is any effect in tumor ethiopathology, maintenance and
progression, it is difficult to judge.
The loss of Shh in Cushing tumors is very striking. There is no Shh or Gli1
expression at all in all Cushing tumors studied. 
Shh inhibits AtT-20 cell proliferation in culture conditions, while the effect on the
pituitary primary culture is impossible to test as these cells do not proliferate. 
It might well be that Shh is necessary for the maintenance of a low/non proliferation
state in the corticotrophs. This is also supported by the development data: Shh must
be absolutely present in the embryo, but excluded from the Rathke’s pouch in the first
stages of pituitary organogenesis to allow proliferation. According to our hypothesis,
this may allow pituitary stem cells to proliferate and differentiate, but the Shh
signaling may be needed later on to stop the proliferation and help in the hormone
secreting activity, at least in corticotrophs.
The results presented here support the hypothesis that in the absence of Shh,
corticotroph cells proliferate more and this could lead to adenoma formation.
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6. Summary
This work investigates for the first time the expression and the role of Sonic
hedgehog signaling pathway in adult pituitary and in pituitary tumors. Shh is a
signaling protein, important in regulating patterning and proliferation in the embryo
and the adult. It has a crucial role in pituitary development and Shh deficient mice do
not even have a rudimentary Rathke’s pouch (the development structure that gives
rise to anterior pituitary). 
This study reveals the presence of an active Shh pathway in the post-developmental
pituitary gland, with major impacts on hormone secretion and cell proliferation. 
After embryonic development, Shh continues to be expressed in the normal adult
pituitary, being mainly co-localized in corticotrophs. These cells express also the
receptor Ptc2 and the Shh induced transcription factor Gli1, being so Shh-producing
and Shh-responsive cells. Shh acts in an autocrine way inside corticotrophs, inducing
a major stimulation of ACTH secretion in the normal rat pituitary and in the AtT-20
cell line. 
The Shh induced ACTH secretion effect is synergistic with CRH. Shh stimulation
increases CRH-R1 levels, up-regulating so the response of corticotrophs to CRH. At
the same time, Gli1 is not only activated by Shh, but also by CRH and PKA. Gli1 itself
activates POMC-transcription and acts in parallel upstream to CREB and AP-1. A
major increase in Shh protein levels is seen as a result of CRH stimulation. All these
results put in evidence a multiple cross-talk between these two important pathways
acting at different levels to insure the final ACTH stimulation.
Other types of hormone-secreting adenohypophysial cells possess one of Shh
receptors (Ptc1 or Ptc2) and the transcription factor Gli1, so they have an active Shh
pathway. Shh produced in the corticotrophs is a signaling protein, so it diffuses and
acts also in distance.  Shh increases GH secretion from the rat pituitary somatotrophs
and from the GH3 cell line, while the effect on Prolactin is not statistically significant.
The Sonic hedgehog pathway is downregulated in pituitary adenomas. Screening of
55 pituitary tumors reveals that they have a significantly reduced expression of Shh
and Gli1. Although Shh in the normal pituitary  is secreted by corticotroph cells, all
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the Cushing tumors screened had no Shh expression at all. Cell culture experiments
performed in the AtT-20 corticotroph cell line in vitro show that Shh reduces cell
proliferation by 50% and this effect is partially reducible by Cyclopamine. So Shh
maintains the low proliferative capacity of corticotrophs in the normal pituitary gland
and its loss may be one of the factors leading to tumor progression.
It is concluded that Shh is produced in the anterior pituitary gland, is a major
stimulant of ACTH and GH secretion, acts synergistically with CRH, opposes
corticotroph cell proliferation and is downregulated in pituitary adenomas.
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6.1 Zusammenfassung
In der vorliegenden Arbeit wurde erstmals die Expression und die Rolle des Sonic
Hedgehog (Shh) Signalweges in adulten Hypophysen und Hypophysentumoren
untersucht. Shh ist ein Signalprotein, das im Embryo und beim Erwachsenen wichtig
für die Regulation der Zelldifferenzierung und –proliferation ist. Es ist für die
Entwicklung der Hypophyse von herausragender Bedeutung, da Shh-defiziente
Mäuse noch nicht einmal eine rudimentäre Rathkesche Tasche (aus der sich der
Hypophysenvorderlappen entwickelt) bilden können. 
Die hier präsentierte Untersuchung zeigt, daß es in der voll entwickelten Hypophyse
einen aktiven Shh-Signaltransduktionsweg gibt, der von beträchtlicher Bedeutung für
die Hormonsekretion und Zellproliferation ist.
Nach der Embryonalentwicklung wird Shh weiter in der normalen, erwachsenen
Hypophyse exprimiert, wobei es vorwiegend in kortikotropen Zellen lokalisiert ist.
Diese Zellen exprimieren auch den Shh-Rezeptor Ptc2 und den Shh-induzierten
Transkriptionsfaktor Gli1 und sind somit sowohl Shh-produzierende als auch Shh-
responsive Zellen. Shh wirkt auf autokrine Weise in den kortikotropen Zellen, indem
es eine erhebliche Stimulation der ACTH Sekretion in der normalen Hypophyse und
in der kortikotropen AtT20 Zelllinie induziert.
Shh wirkt synergistisch mit CRH auf die Induktion der ACTH Freisetzung. Die
Stimulation mit Shh erhöht die Expression des CRH-Typ 1 Rezeptors (CRH-R1) und
erhöht so die Empfindlichkeit kortikotroper Zellen auf CRH. Gleichzeitig wird Gli1
nicht nur durch Shh, sondern auch durch CRH und PKA erhöht. Gli1 selbst aktiviert
die POMC Transkription parallel zu CREB und AP-1. Ein erheblicher Anstieg der
Shh-Proteinspiegel wird nach CRH-Stimulation beobachtet. In ihrer Gesamtheit
weisen diese Ergebnisse auf vielfältige Interaktonen auf unterschiedlichen Ebenen
zwischen diesen zwei wichtigen Signalwegen hin, um letztlich die ACTH Stimulation
zu gewährleisten. 
Auch andere hormonsezernierende Hypophysenzellen besitzen einen der Shh-
Rezeptoren (Ptc1 oder Ptc2) und den Transkriptionsfaktor Gli1 und haben daher ein
aktives Shh-System. Shh, das in kortikotropen Zellen gebildet wird, ist ein
Signalprotein, das nach Diffusion auch in einiger Entfernung in benachbarten Zellen
wirksam ist. Shh steigert die GH Sekretion in somatotropen Zellen und in
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laktosomatotropen GH3 Zellen, während sein Effekt auf Prolaktin statistisch nicht
signifikant ist.
Der Shh-Signaltransduktionsweg ist in Hypophysenadenomen herunterreguliert. Die
Untersuchung von 55 Hypophysenadenomen ergab, daß in den Tumoren die
Expression von Shh und Gli1 signifikant reduziert ist. Obwohl in der normalen
Hypophyse Shh von kortikotropen Zellen sezerniert wird, exprimierten alle
untersuchten kortikotropen Adenome überhaupt kein Shh. Zellkulturexperimente mit
AtT20 Zellen zeigten, daß Shh die Zellproliferation um 50 % reduzierte und daß
dieser Effekt teilweise durch Cyclopamine, einem Inhibitor des Shh-
Signaltransduktionsweges, aufgehoben werden kann. Das weist darauf hin, daß Shh
für die geringe proliferative Kapazität von kortikotropen Zellen in der normalen
Hypophyse verantwortlich ist, und daß sein Verlust einer der Gründe ist, die zur
Progression von Hypophysentumoren führen.
Zusammenfassend kann man feststellen, daß Shh im Hypophysenvorderlappen
produziert wird, daß es ein bedeutender Stimulator der ACTH und GH Sekretion ist,
daß es syergistisch mit CRH wirkt, daß es der Proliferation von kortikotropen Zellen
entgegenwirkt und daß es in Hypophysenadenomen herunterreguliert ist.        
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